{"xm1qBO0AAAAJ": [["Susan H Fox", 2020, "Initiation of pharmacological therapy in Parkinson's disease: when, why, and how"], ["Carl E Clarke", 2020, "Initiation of pharmacological therapy in Parkinson's disease: when, why, and how"], ["Alberto J Espay", 2020, "Initiation of pharmacological therapy in Parkinson's disease: when, why, and how"], ["Rob MA de Bie", 2020, "Initiation of pharmacological therapy in Parkinson's disease: when, why, and how"], ["Carine W Maurer", 2020, "Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: Changes in the last decade"], ["Kathrin LaFaver", 2020, "Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: Changes in the last decade"], ["MDS FMD Study Group", 2020, "Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: Changes in the last decade"], ["Sarah Lidstone", 2020, "Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: Changes in the last decade"], ["Francesca Morgante", 2020, "Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: Changes in the last decade"], ["Mark Edwards", 2020, "Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: Changes in the last decade"], ["Alok K Dwivedi", 2020, "Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: Changes in the last decade"], ["Jon Stone", 2020, "Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: Changes in the last decade"], ["Mark Hallett", 2020, "Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: Changes in the last decade"], ["Julien F Bally", 2020, "Comment on:\u201cIgLON5-mediated neurodegeneration is a differential diagnosis of CNS Whipple disease\u201d"], ["Naomi P Visanji", 2020, "Reply to Woulfe and colleagues."], ["GG Kovacs", 2020, "A systematic neuropathologic evaluation of Down syndrome: A complex multiproteinopathy"], ["AE Lang", 2020, "A systematic neuropathologic evaluation of Down syndrome: A complex multiproteinopathy"], ["NP Visanji", 2020, "A systematic neuropathologic evaluation of Down syndrome: A complex multiproteinopathy"], ["A Maluach", 2020, "A systematic neuropathologic evaluation of Down syndrome: A complex multiproteinopathy"], ["James Saravanamuttu", 2020, "Interhemispheric pathways in agenesis of the corpus callosum and Parkinson\u2019s disease"], ["Robert Chen", 2020, "Interhemispheric pathways in agenesis of the corpus callosum and Parkinson\u2019s disease"], ["Karlo J Lizarraga", 2020, "Interhemispheric pathways in agenesis of the corpus callosum and Parkinson\u2019s disease"], ["Julianne K Baarb\u00e9", 2020, "Interhemispheric pathways in agenesis of the corpus callosum and Parkinson\u2019s disease"], ["Markus Reuber", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["David G Anderson", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["David L Perez", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Bridget Mildon", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Ali A Asadi-Pooya", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Bastiaan R Bloem", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Alan J Carson", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Steven A Epstein", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["B\u00e9atrice Garcin", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Laura H Goldstein", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Clare Nicholson", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Lorna Myers", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Gaston Baslet", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Michele Tinazzi", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Maria Damianova", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Richard A Kanaan", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Timothy R Nicholson", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Selma Aybek", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Marina AJ Tijssen", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Paul Shotbolt", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Karen S Rommelfanger", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Susannah Pick", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Mark J Edwards", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Tereza Serranova", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Richard J Brown", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Stoyan Popkirov", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Joseph Jankovic", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Glenn Nielsen", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Roxanne C Keynejad", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Trudie Chalder", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["W Curt LaFrance Jr", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Eileen M Joyce", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Petra Schwingenshuh", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Kasia Kozlowska", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Glenn T Stebbins", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Anthony S David", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Alex Lehn", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Abigail Bradley-Westguard", 2020, "Outcome measurement in functional neurological disorder: a systematic review and recommendations"], ["Michael A Schwarzschild", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["Ziv Gan-Or", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["Patrik Brundin", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["Philippe L Bedard", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["Jeffrey H Kordower", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["Steven M Rowe", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["Chris S Coffey", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["Benjamin Stecher", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["Marcelo A Kauffman", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["Todd Sherer", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["Alfonso Fasano", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["Antonio P Strafella", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["Jesse M Cedarbaum", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["Andrew B Singleton", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["Andres Lozano", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["Caroline H Williams-Gray", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["Matthew J Farrer", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["Lorraine V Kalia", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["Ronald B Postuma", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["C Warren Olanow", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["David G Standaert", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["Roger A Barker", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["Karl Kieburtz", 2020, "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?"], ["Y Tse", 2020, "A156 LOW COMPLICATION RATE IN THE OUTPATIENT INTRAJEJUNAL LEVODOPA/CARBIDOPA INTESTINAL GEL CLINICAL PROGRAM"], ["LW Liu", 2020, "A156 LOW COMPLICATION RATE IN THE OUTPATIENT INTRAJEJUNAL LEVODOPA/CARBIDOPA INTESTINAL GEL CLINICAL PROGRAM"], ["CH Parker", 2020, "A156 LOW COMPLICATION RATE IN THE OUTPATIENT INTRAJEJUNAL LEVODOPA/CARBIDOPA INTESTINAL GEL CLINICAL PROGRAM"], ["A Fasano", 2020, "A156 LOW COMPLICATION RATE IN THE OUTPATIENT INTRAJEJUNAL LEVODOPA/CARBIDOPA INTESTINAL GEL CLINICAL PROGRAM"], ["A Lang", 2020, "A156 LOW COMPLICATION RATE IN THE OUTPATIENT INTRAJEJUNAL LEVODOPA/CARBIDOPA INTESTINAL GEL CLINICAL PROGRAM"], ["T Naranian", 2020, "A156 LOW COMPLICATION RATE IN THE OUTPATIENT INTRAJEJUNAL LEVODOPA/CARBIDOPA INTESTINAL GEL CLINICAL PROGRAM"], ["N Al Yatama", 2020, "A156 LOW COMPLICATION RATE IN THE OUTPATIENT INTRAJEJUNAL LEVODOPA/CARBIDOPA INTESTINAL GEL CLINICAL PROGRAM"], ["Antonella Macerollo", 2020, "Contingent negative variation: a biomarker of abnormal attention in Functional Movement Disorders"], ["Tiago Teodoro", 2020, "Contingent negative variation: a biomarker of abnormal attention in Functional Movement Disorders"], ["Anthony Lang", 2020, "Contingent negative variation: a biomarker of abnormal attention in Functional Movement Disorders"], ["Akihiro Koreki", 2020, "Contingent negative variation: a biomarker of abnormal attention in Functional Movement Disorders"], ["Anne Marthe Meppelink", 2020, "Contingent negative variation: a biomarker of abnormal attention in Functional Movement Disorders"], ["Isabel Pare\u00e9s", 2020, "Contingent negative variation: a biomarker of abnormal attention in Functional Movement Disorders"], ["Joaquim J Ferreira", 2020, "Contingent negative variation: a biomarker of abnormal attention in Functional Movement Disorders"], ["Simon Little", 2020, "Contingent negative variation: a biomarker of abnormal attention in Functional Movement Disorders"], ["Angelika Reiner", 2020, "Deposits of disease-associated alpha-synuclein may be present in the dura mater in Lewy body disorders: implications for potential inadvertent transmission by surgery"], ["Gabor G Kovacs", 2020, "Deposits of disease-associated alpha-synuclein may be present in the dura mater in Lewy body disorders: implications for potential inadvertent transmission by surgery"], ["Herbert Budka", 2020, "Deposits of disease-associated alpha-synuclein may be present in the dura mater in Lewy body disorders: implications for potential inadvertent transmission by surgery"], ["Peter Fischer", 2020, "Deposits of disease-associated alpha-synuclein may be present in the dura mater in Lewy body disorders: implications for potential inadvertent transmission by surgery"], ["Selma H\u00f6nigschnabl", 2020, "Deposits of disease-associated alpha-synuclein may be present in the dura mater in Lewy body disorders: implications for potential inadvertent transmission by surgery"], ["Ellen Gelpi", 2020, "Deposits of disease-associated alpha-synuclein may be present in the dura mater in Lewy body disorders: implications for potential inadvertent transmission by surgery"], ["Anna Chang", 2020, "Recurrent neurologic symptoms complicating venom immunotherapy in a patient with systemic mastocytosis and severe Hymenoptera allergy"], ["Martina Trinkaus", 2020, "Recurrent neurologic symptoms complicating venom immunotherapy in a patient with systemic mastocytosis and severe Hymenoptera allergy"], ["Baruch D Jakubovic", 2020, "Recurrent neurologic symptoms complicating venom immunotherapy in a patient with systemic mastocytosis and severe Hymenoptera allergy"], ["Amanda Jagdis", 2020, "Recurrent neurologic symptoms complicating venom immunotherapy in a patient with systemic mastocytosis and severe Hymenoptera allergy"], ["Stephen Betschel", 2020, "Recurrent neurologic symptoms complicating venom immunotherapy in a patient with systemic mastocytosis and severe Hymenoptera allergy"], ["Tara Rastin", 2020, "Recurrent neurologic symptoms complicating venom immunotherapy in a patient with systemic mastocytosis and severe Hymenoptera allergy"], ["Mariana Castells", 2020, "Recurrent neurologic symptoms complicating venom immunotherapy in a patient with systemic mastocytosis and severe Hymenoptera allergy"], ["Susen Schaake", 2020, "Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency?"], ["Aleksandar Rakovic", 2020, "Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency?"], ["David P Breen", 2020, "Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency?"], ["Joanne Trinh", 2020, "Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency?"], ["Christine Klein", 2020, "Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency?"], ["Seyed Amir Hassan Habibi", 2020, "Tongue protrusion dystonia in pantothenate kinase-associated neurodegeneration"], ["Foad Kazemi", 2020, "Tongue protrusion dystonia in pantothenate kinase-associated neurodegeneration"], ["Ahmad Chitsaz", 2020, "Tongue protrusion dystonia in pantothenate kinase-associated neurodegeneration"], ["Mohammad Rohani", 2020, "Tongue protrusion dystonia in pantothenate kinase-associated neurodegeneration"], ["Abbas Tafakhori", 2020, "Tongue protrusion dystonia in pantothenate kinase-associated neurodegeneration"], ["Yasaman Saeedi", 2020, "Tongue protrusion dystonia in pantothenate kinase-associated neurodegeneration"], ["S Pablo Sardi", 2020, "Author response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases"], ["James B Leverenz", 2020, "Author response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases"], ["Luca Marsili", 2020, "Author response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases"], ["Joaquin A Vizcarra", 2020, "Author response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases"], ["Sarah C Lidstone", 2020, "Integrated therapy for functional movement disorders: time for a change"], ["Lindsey MacGillivray", 2020, "Integrated therapy for functional movement disorders: time for a change"], ["David J Irwin", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Jean Christophe Corvol", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Gesine Respondek", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Gerard Schellenberg", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Ulrich M\u00fcller", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Claire Troakes", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Leslie W Ferguson", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Alex Rajput", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Franziska Hopfner", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Jennifer L Whitwell", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Elisabet Englund", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Max\u2010Joseph Grimm", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Maria Stamelou", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Armin Giese", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Murray Grossman", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Kailash P Bhatia", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Matthias H\u00f6llerhage", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Lawrence I Golbe", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Sigrun Roeber", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["G\u00fcnter U H\u00f6glinger", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Angelo Antonini", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Thomas Arzberger", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["John C van Swieten", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Ruji Sakakibara", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Huw R Morris", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Dennis W Dickson", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Ines Piot", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Carlo Colosimo", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Paolo Barone", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["James B Rowe", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Jan Kassubek", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Adam K Boxer", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Keith A Josephs", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Wassilios G Meissner", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Johannes Levin", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Ikuko Aiba", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Irene Litvan", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Wolfgang H Oertel", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Christer Nilsson", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Nikolaus McFarland", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Yaroslau Compta", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Gregor K Wenning", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Thilo van Eimeren", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Alexander Pantelyat", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Movement Disorder Society\u2013Endorsed Progressive Supranuclear Palsy Study Group", 2020, "Validation of the movement disorder society criteria for the diagnosis of 4\u2010repeat tauopathies"], ["Hetshree Joshi", 2020, "Decreased Expression of Cerebral Dopamine Neurotrophic Factor in Platelets of Stroke Patients"], ["Simona Gabriele", 2020, "Decreased Expression of Cerebral Dopamine Neurotrophic Factor in Platelets of Stroke Patients"], ["Ram K Mishra", 2020, "Decreased Expression of Cerebral Dopamine Neurotrophic Factor in Platelets of Stroke Patients"], ["Michel Rathbone", 2020, "Decreased Expression of Cerebral Dopamine Neurotrophic Factor in Platelets of Stroke Patients"], ["William Brett McIntyre", 2020, "Decreased Expression of Cerebral Dopamine Neurotrophic Factor in Platelets of Stroke Patients"], ["Joseph Gabriele", 2020, "Decreased Expression of Cerebral Dopamine Neurotrophic Factor in Platelets of Stroke Patients"], ["David Baranowski", 2020, "Decreased Expression of Cerebral Dopamine Neurotrophic Factor in Platelets of Stroke Patients"], ["Sharnpreet Kooner", 2020, "Decreased Expression of Cerebral Dopamine Neurotrophic Factor in Platelets of Stroke Patients"], ["Benicio N Frey", 2020, "Decreased Expression of Cerebral Dopamine Neurotrophic Factor in Platelets of Stroke Patients"], ["Claudio L Bassetti", 2020, "What is the role of a specialist assessment clinic for FND? lessons from three national referral centers"], ["Justin J Lang", 2019, "Aper\u00e7u-Incidence de la mortalit\u00e9 par intoxication sur l'esp\u00e9rance de vie \u00e0 la naissance au Canada (2000-2016)."], ["Diana George", 2019, "Aper\u00e7u-Incidence de la mortalit\u00e9 par intoxication sur l'esp\u00e9rance de vie \u00e0 la naissance au Canada (2000-2016)."], ["Jessica Halverson", 2019, "Aper\u00e7u-Incidence de la mortalit\u00e9 par intoxication sur l'esp\u00e9rance de vie \u00e0 la naissance au Canada (2000-2016)."], ["Heather M Orpana", 2019, "Aper\u00e7u-Incidence de la mortalit\u00e9 par intoxication sur l'esp\u00e9rance de vie \u00e0 la naissance au Canada (2000-2016)."], ["Karen Misquitta", 2019, "Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer\u2019s Disease, Parkinson\u2019s Disease, and Healthy Controls"], ["Anne Catherine Vijverman", 2019, "Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer\u2019s Disease, Parkinson\u2019s Disease, and Healthy Controls"], ["Cassandra Anor", 2019, "Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer\u2019s Disease, Parkinson\u2019s Disease, and Healthy Controls"], ["Namita Multani", 2019, "Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer\u2019s Disease, Parkinson\u2019s Disease, and Healthy Controls"], ["Ron Keren", 2019, "Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer\u2019s Disease, Parkinson\u2019s Disease, and Healthy Controls"], ["Connie Marras", 2019, "Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer\u2019s Disease, Parkinson\u2019s Disease, and Healthy Controls"], ["Susan Fox", 2019, "Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer\u2019s Disease, Parkinson\u2019s Disease, and Healthy Controls"], ["Foad Taghdiri", 2019, "Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer\u2019s Disease, Parkinson\u2019s Disease, and Healthy Controls"], ["Brenda Varriano", 2019, "Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer\u2019s Disease, Parkinson\u2019s Disease, and Healthy Controls"], ["Maria Carmela Tartaglia", 2019, "Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer\u2019s Disease, Parkinson\u2019s Disease, and Healthy Controls"], ["David France Tang-Wai", 2019, "Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer\u2019s Disease, Parkinson\u2019s Disease, and Healthy Controls"], ["Richard Camicioli", 2019, "Orthostatic hypotension and dementia incidence: links and implications"], ["Sean J Udow", 2019, "Orthostatic hypotension and dementia incidence: links and implications"], ["Aristide Merola", 2019, "Orthostatic hypotension and dementia incidence: links and implications"], ["Mario Masellis", 2019, "Orthostatic hypotension and dementia incidence: links and implications"], ["Andrew D Robertson", 2019, "Orthostatic hypotension and dementia incidence: links and implications"], ["Solange Kapetanovic", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["David Valle", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Andrew Chancellor", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Phillip Cremer", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Peter Diakumis", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Mike Eberle", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["David Szmulewicz", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["David Zee", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Weiyi Mu", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Mark Bennett", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Anna Hackett", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Elsdon Storey", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Ian Rosemargy", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Martin Delatycki", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Paul J Lockhart", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Mar\u00eda Garc\u00eda Barcina", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["David Breen", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Peter Patrikios", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Haloom Rafehi", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Egor Dolzhenko", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Nara Sobreira", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Brent Fogel", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Greta Gillies", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Katherine Smith", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Kate Pope", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Melanie Bahlo", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["G Michael Halmagyi", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Susan Perlman", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Stuart Mossman", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["David Amor", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Shaun Watson", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Michael Wilson", 2019, "Validation of new bioinformatic tools to identify expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS"], ["Carolyn Gotay", 2019, "Assessment of the burden of diseases and injuries attributable to risk factors in Canada from 1990 to 2016: an analysis of the Global Burden of Disease Study"], ["Scott B Patten", 2019, "Assessment of the burden of diseases and injuries attributable to risk factors in Canada from 1990 to 2016: an analysis of the Global Burden of Disease Study"], ["Leah E Cahill", 2019, "Assessment of the burden of diseases and injuries attributable to risk factors in Canada from 1990 to 2016: an analysis of the Global Burden of Disease Study"], ["Samiah Alam", 2019, "Assessment of the burden of diseases and injuries attributable to risk factors in Canada from 1990 to 2016: an analysis of the Global Burden of Disease Study"], ["Kedar Mate", 2019, "Assessment of the burden of diseases and injuries attributable to risk factors in Canada from 1990 to 2016: an analysis of the Global Burden of Disease Study"], ["Ashkan Afshin", 2019, "Assessment of the burden of diseases and injuries attributable to risk factors in Canada from 1990 to 2016: an analysis of the Global Burden of Disease Study"], ["Aaron M Drucker", 2019, "Assessment of the burden of diseases and injuries attributable to risk factors in Canada from 1990 to 2016: an analysis of the Global Burden of Disease Study"], ["Nicole Kozloff", 2019, "Assessment of the burden of diseases and injuries attributable to risk factors in Canada from 1990 to 2016: an analysis of the Global Burden of Disease Study"], ["Alice Bernard", 2018, "Serum inflammatory profile for the discrimination of clinical subtypes in Parkinson's disease"], ["Walter Maetzler", 2018, "Serum inflammatory profile for the discrimination of clinical subtypes in Parkinson's disease"], ["Thomas O Joos", 2018, "Serum inflammatory profile for the discrimination of clinical subtypes in Parkinson's disease"], ["Clint Hansen", 2018, "Serum inflammatory profile for the discrimination of clinical subtypes in Parkinson's disease"], ["Rezzak Yilmaz", 2018, "Serum inflammatory profile for the discrimination of clinical subtypes in Parkinson's disease"], ["Lieneke van den Heuvel", 2018, "Serum inflammatory profile for the discrimination of clinical subtypes in Parkinson's disease"], ["Nicole Schneiderhan-Marra", 2018, "Serum inflammatory profile for the discrimination of clinical subtypes in Parkinson's disease"], ["Frank Leypoldt", 2018, "Serum inflammatory profile for the discrimination of clinical subtypes in Parkinson's disease"], ["Thomas Gasser", 2018, "Serum inflammatory profile for the discrimination of clinical subtypes in Parkinson's disease"], ["Thomas Knorpp", 2018, "Serum inflammatory profile for the discrimination of clinical subtypes in Parkinson's disease"], ["Sebastian Heinzel", 2018, "Serum inflammatory profile for the discrimination of clinical subtypes in Parkinson's disease"], ["Daniela Berg", 2018, "Serum inflammatory profile for the discrimination of clinical subtypes in Parkinson's disease"], ["Johanna Geritz", 2018, "Serum inflammatory profile for the discrimination of clinical subtypes in Parkinson's disease"], ["Claudia Schulte", 2018, "Serum inflammatory profile for the discrimination of clinical subtypes in Parkinson's disease"], ["Anja Apel", 2018, "Serum inflammatory profile for the discrimination of clinical subtypes in Parkinson's disease"], ["Barbara Picconi", 2018, "Levodopa\u2010induced dyskinesia in Parkinson disease: Current and evolving concepts"], ["Erwan Bezard", 2018, "Levodopa\u2010induced dyskinesia in Parkinson disease: Current and evolving concepts"], ["Paolo Calabresi", 2018, "Levodopa\u2010induced dyskinesia in Parkinson disease: Current and evolving concepts"], ["I Litvan", 2018, "1.5. 4 Kortikobasale Degeneration"], ["MJ Armstrong", 2018, "1.5. 4 Kortikobasale Degeneration"], ["Amitava Banerjee", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Joseph Adel Mattar Banoub", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Khurshid Alam", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Leticia Avila-Burgos", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Aleksandra Barac", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Hamid Badali", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Mustafa Geleto Ansha", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Rizwan Suliankatchi Abdulkader", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Kefyalew Addis Alene", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Jason A Anderson", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Syed Mohamed Aljunid", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Pawan Acharya", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Sanjay Basu", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Krishna K Aryal", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Hesham M Al-Mekhlafi", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Suleman Atique", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Neeraj Bedi", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Ansariadi Ansariadi", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Hedayat Abbastabar", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Haftom Niguse Abraha", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Maciej Banach", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Ammar Albujeer", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Fatma Al-Maskari", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Rajaa M Al-Raddadi", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Walid Ammar", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Mehran Alijanzadeh", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Ala'a Alkerwi", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Catalina Liliana Andrei", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Tomi Akinyemiju", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Sayem Ahmed", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Nahla Hamed Anber", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Lambert Tetteh Appiah", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Nancy Fullman", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Palwasha Anwari", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Quique Bassat", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Mina Anjomshoa", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Nebiyu Dereje Abebe", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Abdu A Adamu", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Raghib Ali", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Natasha Azzopardi-Muscat", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Ali Almasi", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Tesleem Kayode Babalola", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Mohammad Esmaeil Akbari", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Foad Abd-Allah", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Hossein Ansari", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Carl Abelardo T Antonio", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Lope H Barrero", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Kalpana Balakrishnan", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Ibrahim Abdollahpour", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Oladimeji M Adebayo", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Zegeye Abebe", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Tahiya Alam", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Alaa Badawi", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Habtamu Wondifraw Baynes", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Mina G Adib", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Nelson Alvis-Guzman", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Ettore Beghi", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Madhu Sudhan Atteraya", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Victor Aboyans", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Azmeraw T Amare", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Alireza Ahmadi", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Jemal Abdela", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Beatriz Paulina Ayala Quintanilla", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Rufus Olusola Akinyemi", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Temesgen Yihunie Akalu", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Nadia Akseer", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Fran\u00e7ois Alla", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Ubai Alsharif", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Ahmed Abdelalim", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Gina Agarwal", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Ars\u00e8ne Kouablan Adou", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Omar Abdel-Rahman", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Johan \u00c4rnl\u00f6v", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Victor Adekanmbi", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Nooshin Abbasi", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Tara Ballav Adhikari", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Cristiana Abbafati", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Arefeh Babazadeh", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Dominic Agius", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Ayman Al-Eyadhy", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Khalid Altirkawi", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Reza Assadi", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Laith Jamal Abu-Raddad", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Semaw F Abera", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Jordi Alonso", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Dilaram Acharya", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Yohanes Ayele", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Miguel A Barboza", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Christine A Allen", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Megbaru Debalkie Animut", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Celine M Barthelemy", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Ayele Geleto Bali", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Degu Abate", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Rafael Lozano", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Manfred Mario Kokou Accrombessi", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Sutapa Agrawal", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Monika Arora", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Marcel Ausloos", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Bernhard T Baune", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Aklilu Roba Abrham", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Shahrzad Bazargan-Hejazi", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Peter S Azzopardi", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Niveen Me Abu-Rmeileh", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Olatunji O Adetokunboh", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Peter Allebeck", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Hamid Asayesh", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Mohammed Akibu", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Beyene Meressa Adhena", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Mahdi Afshari", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Anurag Agrawal", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Animut Alebel", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Gebre Y Abyu", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Fares Alahdab", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Olatunde Aremu", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Sachin R Atre", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Erfan Amini", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Zerihun Ataro", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Ashish Awasthi", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Samia Alhabib", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Ali S Akanda", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Muktar Beshir Ahmed", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Mohsen Afarideh", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Robert J Battista", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Henok Tadesse Ayele", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Jose C Adsuar", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Till Winfried B\u00e4rnighausen", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Rufus Adesoji Adedoyin", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Olifan Zewdie Abil", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Hamid Ahmadieh", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Habtamu Abera Areri", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Rakesh Ayer", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Sargis Aghasi Aghayan", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Solomon M Abay", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Suzanne Lyn Barker-Collo", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Isaac Akinkunmi Adedeji", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Ziyad Al-Aly", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Kebede Amenu", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Reza Alizadeh-Navaei", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Mahmoud Reza Azarpazhooh", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Mehdi Ahmadi", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Ephrem Tsegay Asfaw", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Alireza Abdi", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Solomon Weldegebreal Asgedom", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Amrit Banstola", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Ayenew Negesse Abejie", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Sofia Androudi", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Arindam Basu", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Euripide FGA Avokpaho", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Rana Jawad Asghar", 2018, "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic \u2026"], ["Miloud Taki Eddine Aichour", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Niveen ME Abu-Rmeileh", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Meysam Behzadifar", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Masoud Behzadifar", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Kalkidan Hassen Abate", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Adugnaw Berhane", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Al Artaman", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Xie Rachel Kulikoff", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Tambe B Ayuk", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Michelle L Bell", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Teshome Abuka Abebo", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Isabela M Bensenor", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Daisy Maria Xavier Abreu", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Bayu Begashaw Bekele", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Ibtihel Aichour", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Amani Nidhal Aichour", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Suraj Bhattarai", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Derrick A Bennett", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Adam E Berman", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Yihalem Abebe Belay", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Mircea Beuran", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Nigus Bililign", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Kareha M Agesa", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Alicia V Aleman", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Belete Biadgo", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Saba Abraham Belay", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Tesfay Mehari Mehari Atey", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Gilles Bergeron", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Haftom Temesgen Abebe", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Nasrin Abdoli", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Seth Christopher Yaw Appiah", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Abate Bekele Belachew", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Charlton SKH Callender", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Christopher JL Murray", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Ali Bijani", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Zulfiqar A Bhutta", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Eduardo Bernabe", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Boris Bikbov", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Robert S Bernstein", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Soumyadeep Bhaumik", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Nicholas Arian", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Huda Basaleem", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Gregory J Bertolacci", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Vinay Srinivasan", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Ezra Belay", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Aregawi Gebreyesus Belay", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Aminu K Bello", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Molla Abebe", 2018, "Population and fertility by age and sex for 195 countries and territories, 1950\u20132017: a systematic analysis for the Global Burden of Disease Study 2017"], ["Tina Beyranvand", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Archie Bleyer", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Seyed Moayed Alavian", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Mohammadreza Amiresmaili", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Ilana N Ackerman", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Alexandra Brazinova", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Donal Bisanzio", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Rakesh Aggarwal", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Hmwe Hmwe Kyu", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Rupert Bourne", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Eyasu Tamru Bekru", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Molly H Biehl", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Soufiane Boufous", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Leopold N Aminde", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Nicholas JK Breitborde", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Muhammad Shahdaat Bin Sayeed", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Eshetu Mulisa Bobasa", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Yaw Ampem Amoako", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Amit Arora", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Zanfina Ademi", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Ver Bilano", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Megha Arora", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Alaa Alashi", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Jalal Arabloo", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Kossivi Agbelenko Afanvi", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Samir Bhatt", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Neeraj Bhala", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Ibrahim R Bou-Orm", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Tone Bj\u00f8rge", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Luisa C Brant", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Carol Brayne", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Oliver J Brady", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Simon Barquera", 2018, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 \u2026"], ["Josep M Ant\u00f3", 2018, "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and \u2026"], ["Kylie Ball", 2018, "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and \u2026"], ["Komal Ali", 2018, "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and \u2026"], ["Yannick B\u00e9jot", 2018, "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and \u2026"], ["Akilew Awoke Adane", 2018, "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and \u2026"], ["Anju Aggarwal", 2018, "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and \u2026"], ["Shoshana H Ballew", 2018, "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and \u2026"], ["Syed Mustafa Ali", 2018, "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and \u2026"], ["Tuhin Biswas", 2018, "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and \u2026"], ["Emmanuela Gakidou", 2018, "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and \u2026"], ["Brigette F Blacker", 2018, "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and \u2026"], ["Ashish Bhalla", 2018, "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and \u2026"], ["Amha Admasie", 2018, "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and \u2026"], ["Jeffrey D Stanaway", 2018, "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and \u2026"], ["Stephen S Lim", 2018, "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and \u2026"], ["Kedar KV Mate", 2018, "Global Burden of Disease Study trends for Canada from 1990 to 2016"], ["Jeanne F Kayibanda", 2018, "Global Burden of Disease Study trends for Canada from 1990 to 2016"], ["Francisco B Ortega", 2018, "European normative values for physical fitness in children and adolescents aged 9\u201317 years: results from 2 779 165 Eurofit performances representing 30 countries"], ["Grant R Tomkinson", 2018, "European normative values for physical fitness in children and adolescents aged 9\u201317 years: results from 2 779 165 Eurofit performances representing 30 countries"], ["John S Fitzgerald", 2018, "European normative values for physical fitness in children and adolescents aged 9\u201317 years: results from 2 779 165 Eurofit performances representing 30 countries"], ["Frazer Atkinson", 2018, "European normative values for physical fitness in children and adolescents aged 9\u201317 years: results from 2 779 165 Eurofit performances representing 30 countries"], ["Lucy K Lewis", 2018, "European normative values for physical fitness in children and adolescents aged 9\u201317 years: results from 2 779 165 Eurofit performances representing 30 countries"], ["Kevin D Carver", 2018, "European normative values for physical fitness in children and adolescents aged 9\u201317 years: results from 2 779 165 Eurofit performances representing 30 countries"], ["Nathan D Daniell", 2018, "European normative values for physical fitness in children and adolescents aged 9\u201317 years: results from 2 779 165 Eurofit performances representing 30 countries"], ["Bruce Coate", 2018, "Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive\u2010enhancing medications"], ["Niccole J Larsen", 2018, "Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive\u2010enhancing medications"], ["Doral Fredericks", 2018, "Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive\u2010enhancing medications"], ["Joseph H Friedman", 2018, "Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive\u2010enhancing medications"], ["Michael T Guskey", 2018, "Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive\u2010enhancing medications"], ["Clive Ballard", 2018, "Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive\u2010enhancing medications"], ["Daniel Weintraub", 2018, "Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive\u2010enhancing medications"], ["James C Norton", 2018, "Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive\u2010enhancing medications"], ["Stewart A Factor", 2018, "Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive\u2010enhancing medications"], ["Candace Andersson", 2018, "Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive\u2010enhancing medications"], ["Emily Wolfe Phillips", 2018, "Field-based measurement of cardiorespiratory fitness to evaluate physical activity interventions"], ["Mark S Tremblay", 2018, "Field-based measurement of cardiorespiratory fitness to evaluate physical activity interventions"], ["Diego Augusto Santos Silva", 2018, "Field-based measurement of cardiorespiratory fitness to evaluate physical activity interventions"], ["Robert Ross", 2018, "Field-based measurement of cardiorespiratory fitness to evaluate physical activity interventions"], ["Melanie Anderson", 2018, "Systematic review of movement disorders and oculomotor abnormalities in Whipple's disease"], ["Emmanuel Roze", 2018, "Systematic review of movement disorders and oculomotor abnormalities in Whipple's disease"], ["David Grabli", 2018, "Systematic review of movement disorders and oculomotor abnormalities in Whipple's disease"], ["Aur\u00e9lie M\u00e9neret", 2018, "Systematic review of movement disorders and oculomotor abnormalities in Whipple's disease"], ["Renato P Munhoz", 2018, "ADCK3\u2010related coenzyme Q10 deficiency: a potentially treatable genetic disease"], ["Marta Ruiz\u2010Lopez", 2018, "ADCK3\u2010related coenzyme Q10 deficiency: a potentially treatable genetic disease"], ["Mark Tarnopolsky", 2018, "ADCK3\u2010related coenzyme Q10 deficiency: a potentially treatable genetic disease"], ["Elizabeth Slow", 2018, "ADCK3\u2010related coenzyme Q10 deficiency: a potentially treatable genetic disease"], ["David Oakes", 2018, "Reproducibility of data-driven Parkinson's disease subtypes for clinical research"], ["Caroline Tanner", 2018, "Reproducibility of data-driven Parkinson's disease subtypes for clinical research"], ["David Grimes", 2018, "Reproducibility of data-driven Parkinson's disease subtypes for clinical research"], ["Shirley Eberly", 2018, "Reproducibility of data-driven Parkinson's disease subtypes for clinical research"], ["Tiago A Mestre", 2018, "Reproducibility of data-driven Parkinson's disease subtypes for clinical research"], ["Rajasumi Rajalingam", 2018, "Essential tremor plus is more common than essential tremor: Insights from the reclassification of a cohort of patients with lower limb tremor."], ["Jiun Yan Tan", 2018, "Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease"], ["Ru Peng New", 2018, "Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease"], ["Tun Khong Tay", 2018, "Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease"], ["Siang Lyn Tan", 2018, "Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease"], ["Maw Pin Tan", 2018, "Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease"], ["Shen-Yang Lim", 2018, "Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease"], ["Mohamad Addin Azhan A Manap", 2018, "Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease"], ["Ai Huey Tan", 2018, "Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease"], ["Farhana Fadzli", 2018, "Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease"], ["Yin Cheng Hew", 2018, "Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease"], ["Foong Ming Moy", 2018, "Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease"], ["Mathis Grossmann", 2018, "Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease"], ["Shahrul Bahyah Kamaruzzaman", 2018, "Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease"], ["Eng Jui Yee", 2018, "Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease"], ["Sanjiv Mahadeva", 2018, "Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease"], ["Norlisah Mohd Ramli", 2018, "Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease"], ["Ban Hong Ang", 2018, "Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease"], ["Thomas Schroeter", 2018, "Cardiac Surgery in Patients with Parkinson's Disease: A Retrospective Analysis of a High-Risk Cohort"], ["Muhammed Ikbal Aydin", 2018, "Cardiac Surgery in Patients with Parkinson's Disease: A Retrospective Analysis of a High-Risk Cohort"], ["Maximilian Vondran", 2018, "Cardiac Surgery in Patients with Parkinson's Disease: A Retrospective Analysis of a High-Risk Cohort"], ["Farhad Bakhtiary", 2018, "Cardiac Surgery in Patients with Parkinson's Disease: A Retrospective Analysis of a High-Risk Cohort"], ["Friedrich Wilhelm Mohr", 2018, "Cardiac Surgery in Patients with Parkinson's Disease: A Retrospective Analysis of a High-Risk Cohort"], ["Mahmoud Sleiman Wehbe", 2018, "Cardiac Surgery in Patients with Parkinson's Disease: A Retrospective Analysis of a High-Risk Cohort"], ["Meinhard Mende", 2018, "Cardiac Surgery in Patients with Parkinson's Disease: A Retrospective Analysis of a High-Risk Cohort"], ["Matthias Sauer", 2018, "Cardiac Surgery in Patients with Parkinson's Disease: A Retrospective Analysis of a High-Risk Cohort"], ["JC Corvol", 2018, "PASSPORT, An Ongoing Phase 2 Study in Patients with PSP-Baseline Characteristics"], ["G Hoglinger", 2018, "PASSPORT, An Ongoing Phase 2 Study in Patients with PSP-Baseline Characteristics"], ["J O'Gorman", 2018, "PASSPORT, An Ongoing Phase 2 Study in Patients with PSP-Baseline Characteristics"], ["I Qureshi", 2018, "PASSPORT, An Ongoing Phase 2 Study in Patients with PSP-Baseline Characteristics"], ["T Olsson", 2018, "PASSPORT, An Ongoing Phase 2 Study in Patients with PSP-Baseline Characteristics"], ["A Boxer", 2018, "PASSPORT, An Ongoing Phase 2 Study in Patients with PSP-Baseline Characteristics"], ["H Morris", 2018, "PASSPORT, An Ongoing Phase 2 Study in Patients with PSP-Baseline Characteristics"], ["S Budd Haeberlein", 2018, "PASSPORT, An Ongoing Phase 2 Study in Patients with PSP-Baseline Characteristics"], ["B Han", 2018, "PASSPORT, An Ongoing Phase 2 Study in Patients with PSP-Baseline Characteristics"], ["L Golbe", 2018, "PASSPORT, An Ongoing Phase 2 Study in Patients with PSP-Baseline Characteristics"], ["C Bechtold", 2018, "PASSPORT, An Ongoing Phase 2 Study in Patients with PSP-Baseline Characteristics"], ["M Grundman", 2018, "PASSPORT, An Ongoing Phase 2 Study in Patients with PSP-Baseline Characteristics"], ["T Dam", 2018, "PASSPORT, An Ongoing Phase 2 Study in Patients with PSP-Baseline Characteristics"], ["L Sanchez-Rodriguez", 2018, "Listen to the heart: Do loud vagal rhythms disharmonize the autonomic symphony in Parkinson's disease patients with the LRRK2 mutation?"], ["M Estevez Baez", 2018, "Listen to the heart: Do loud vagal rhythms disharmonize the autonomic symphony in Parkinson's disease patients with the LRRK2 mutation?"], ["C Marras", 2018, "Listen to the heart: Do loud vagal rhythms disharmonize the autonomic symphony in Parkinson's disease patients with the LRRK2 mutation?"], ["C Carricarte Naranjo", 2018, "Listen to the heart: Do loud vagal rhythms disharmonize the autonomic symphony in Parkinson's disease patients with the LRRK2 mutation?"], ["D Cornforth", 2018, "Listen to the heart: Do loud vagal rhythms disharmonize the autonomic symphony in Parkinson's disease patients with the LRRK2 mutation?"], ["S Goldman", 2018, "Listen to the heart: Do loud vagal rhythms disharmonize the autonomic symphony in Parkinson's disease patients with the LRRK2 mutation?"], ["P Stein", 2018, "Listen to the heart: Do loud vagal rhythms disharmonize the autonomic symphony in Parkinson's disease patients with the LRRK2 mutation?"], ["H Jelinek", 2018, "Listen to the heart: Do loud vagal rhythms disharmonize the autonomic symphony in Parkinson's disease patients with the LRRK2 mutation?"], ["A Machado Garcia", 2018, "Listen to the heart: Do loud vagal rhythms disharmonize the autonomic symphony in Parkinson's disease patients with the LRRK2 mutation?"], ["N Visanji", 2018, "Listen to the heart: Do loud vagal rhythms disharmonize the autonomic symphony in Parkinson's disease patients with the LRRK2 mutation?"], ["B Schuele", 2018, "Listen to the heart: Do loud vagal rhythms disharmonize the autonomic symphony in Parkinson's disease patients with the LRRK2 mutation?"], ["J Bowman", 2018, "Unveiling the function of altered gut microbiota composition in Parkinson's disease"], ["MF Loke", 2018, "Unveiling the function of altered gut microbiota composition in Parkinson's disease"], ["JY Tan", 2018, "Unveiling the function of altered gut microbiota composition in Parkinson's disease"], ["CW Chong", 2018, "Unveiling the function of altered gut microbiota composition in Parkinson's disease"], ["AH Tan", 2018, "Unveiling the function of altered gut microbiota composition in Parkinson's disease"], ["BH Ang", 2018, "Unveiling the function of altered gut microbiota composition in Parkinson's disease"], ["CSJ Teh", 2018, "Unveiling the function of altered gut microbiota composition in Parkinson's disease"], ["HS Yong", 2018, "Unveiling the function of altered gut microbiota composition in Parkinson's disease"], ["SL Song", 2018, "Unveiling the function of altered gut microbiota composition in Parkinson's disease"], ["SY Lim", 2018, "Unveiling the function of altered gut microbiota composition in Parkinson's disease"], ["YQ Tan", 2018, "Unveiling the function of altered gut microbiota composition in Parkinson's disease"], ["S Mahadeva", 2018, "Unveiling the function of altered gut microbiota composition in Parkinson's disease"], ["IKS Yap", 2018, "Unveiling the function of altered gut microbiota composition in Parkinson's disease"], ["R Camicioli", 2018, "Prevalence and influence of co-pathologies in patients with autopsy-confirmed Lewy body disorders: A systematic review"], ["J Miyasaki", 2018, "Prevalence and influence of co-pathologies in patients with autopsy-confirmed Lewy body disorders: A systematic review"], ["E Ravid", 2018, "Prevalence and influence of co-pathologies in patients with autopsy-confirmed Lewy body disorders: A systematic review"], ["D Breen", 2018, "Prevalence and influence of co-pathologies in patients with autopsy-confirmed Lewy body disorders: A systematic review"], ["A Espay", 2018, "Pimavanserin Combined With Anti-Dementia Medications for Parkinson Disease Psychosis"], ["B Coate", 2018, "Pimavanserin Combined With Anti-Dementia Medications for Parkinson Disease Psychosis"], ["M Guskey", 2018, "Pimavanserin Combined With Anti-Dementia Medications for Parkinson Disease Psychosis"], ["S Factor", 2018, "Pimavanserin Combined With Anti-Dementia Medications for Parkinson Disease Psychosis"], ["J Friedman", 2018, "Pimavanserin Combined With Anti-Dementia Medications for Parkinson Disease Psychosis"], ["D Weintraub", 2018, "Pimavanserin Combined With Anti-Dementia Medications for Parkinson Disease Psychosis"], ["N Larsen", 2018, "Pimavanserin Combined With Anti-Dementia Medications for Parkinson Disease Psychosis"], ["J Vizcarra", 2018, "Pimavanserin Combined With Anti-Dementia Medications for Parkinson Disease Psychosis"], ["Silvia Rios\u2010Romenets", 2018, "Validation of the MDS clinical diagnostic criteria for Parkinson's disease"], ["Glenda Halliday", 2018, "Validation of the MDS clinical diagnostic criteria for Parkinson's disease"], ["Werner Poewe", 2018, "Validation of the MDS clinical diagnostic criteria for Parkinson's disease"], ["Klaus Seppi", 2018, "Validation of the MDS clinical diagnostic criteria for Parkinson's disease"], ["Taomian Mi", 2018, "Validation of the MDS clinical diagnostic criteria for Parkinson's disease"], ["Simon Lewis", 2018, "Validation of the MDS clinical diagnostic criteria for Parkinson's disease"], ["Ian O Bledsoe", 2018, "Validation of the MDS clinical diagnostic criteria for Parkinson's disease"], ["Piu Chan", 2018, "Validation of the MDS clinical diagnostic criteria for Parkinson's disease"], ["Christopher G Goetz", 2018, "Validation of the MDS clinical diagnostic criteria for Parkinson's disease"], ["Corina Maetzler", 2018, "Validation of the MDS clinical diagnostic criteria for Parkinson's disease"], ["Eva Schaffer", 2018, "Validation of the MDS clinical diagnostic criteria for Parkinson's disease"], ["Beatrice Heim", 2018, "Validation of the MDS clinical diagnostic criteria for Parkinson's disease"], ["Yuan Li", 2018, "Validation of the MDS clinical diagnostic criteria for Parkinson's disease"], ["Joel D Barnes", 2018, "Cardiorespiratory fitness is associated with physical literacy in a large sample of Canadian children aged 8 to 12 years"], ["Kirstin N Lane", 2018, "Cardiorespiratory fitness is associated with physical literacy in a large sample of Canadian children aged 8 to 12 years"], ["Nathan Hall", 2018, "Cardiorespiratory fitness is associated with physical literacy in a large sample of Canadian children aged 8 to 12 years"], ["Jennifer L Copeland", 2018, "Cardiorespiratory fitness is associated with physical literacy in a large sample of Canadian children aged 8 to 12 years"], ["Sarah J Woodruff", 2018, "Cardiorespiratory fitness is associated with physical literacy in a large sample of Canadian children aged 8 to 12 years"], ["Luc J Martin", 2018, "Cardiorespiratory fitness is associated with physical literacy in a large sample of Canadian children aged 8 to 12 years"], ["Kevin Belanger", 2018, "Cardiorespiratory fitness is associated with physical literacy in a large sample of Canadian children aged 8 to 12 years"], ["Angela M Kolen", 2018, "Cardiorespiratory fitness is associated with physical literacy in a large sample of Canadian children aged 8 to 12 years"], ["Melanie J Gregg", 2018, "Cardiorespiratory fitness is associated with physical literacy in a large sample of Canadian children aged 8 to 12 years"], ["Brenda Bruner", 2018, "Cardiorespiratory fitness is associated with physical literacy in a large sample of Canadian children aged 8 to 12 years"], ["Travis J Saunders", 2018, "Cardiorespiratory fitness is associated with physical literacy in a large sample of Canadian children aged 8 to 12 years"], ["Kristal D Anderson", 2018, "Cardiorespiratory fitness is associated with physical literacy in a large sample of Canadian children aged 8 to 12 years"], ["Patricia E Longmuir", 2018, "Cardiorespiratory fitness is associated with physical literacy in a large sample of Canadian children aged 8 to 12 years"], ["Michelle R Stone", 2018, "Cardiorespiratory fitness is associated with physical literacy in a large sample of Canadian children aged 8 to 12 years"], ["Barbi Law", 2018, "Cardiorespiratory fitness is associated with physical literacy in a large sample of Canadian children aged 8 to 12 years"], ["Jean-Philippe Chaput", 2018, "Cardiorespiratory fitness is associated with physical literacy in a large sample of Canadian children aged 8 to 12 years"], ["Dany J MacDonald", 2018, "Cardiorespiratory fitness is associated with physical literacy in a large sample of Canadian children aged 8 to 12 years"], ["Dwayne Sheehan", 2018, "Cardiorespiratory fitness is associated with physical literacy in a large sample of Canadian children aged 8 to 12 years"], ["Inga Liepelt\u2010Scarfone", 2018, "Movement disorder society criteria for clinically established early Parkinson's disease"], ["Kenneth Marek", 2018, "Movement disorder society criteria for clinically established early Parkinson's disease"], ["Wolfgang Oertel", 2018, "Movement disorder society criteria for clinically established early Parkinson's disease"], ["G\u00fcnther Deuschl", 2018, "Movement disorder society criteria for clinically established early Parkinson's disease"], ["Matthew Stern", 2018, "Movement disorder society criteria for clinically established early Parkinson's disease"], ["Jos\u00e9 Obeso", 2018, "Movement disorder society criteria for clinically established early Parkinson's disease"], ["Charles H Adler", 2018, "Movement disorder society criteria for clinically established early Parkinson's disease"], ["Eva Sch\u00e4ffer", 2018, "Movement disorder society criteria for clinically established early Parkinson's disease"], ["Mohammad-Masoud Rahimi Bidgoli", 2018, "Pantothenate kinase-associated neurodegeneration mimicking Tourette syndrome: a case report and review of the literature"], ["Afagh Alavi", 2018, "Pantothenate kinase-associated neurodegeneration mimicking Tourette syndrome: a case report and review of the literature"], ["Leila Javanparast", 2018, "Pantothenate kinase-associated neurodegeneration mimicking Tourette syndrome: a case report and review of the literature"], ["Babak Zamani", 2018, "Pantothenate kinase-associated neurodegeneration mimicking Tourette syndrome: a case report and review of the literature"], ["Ruth H Walker", 2018, "Movement disorders in non-encephalopathic Hashimoto\u2019s thyroiditis"], ["Paola Toche", 2018, "Movement disorders in non-encephalopathic Hashimoto\u2019s thyroiditis"], ["M Leonor Bustamante", 2018, "Movement disorders in non-encephalopathic Hashimoto\u2019s thyroiditis"], ["Marcelo Miranda", 2018, "Movement disorders in non-encephalopathic Hashimoto\u2019s thyroiditis"], ["Mario Campero", 2018, "Movement disorders in non-encephalopathic Hashimoto\u2019s thyroiditis"], ["Eduardo Wainstein", 2018, "Movement disorders in non-encephalopathic Hashimoto\u2019s thyroiditis"], ["Danielle Andrade", 2018, "Neuropsychiatric expression and catatonia in 22q11. 2 deletion syndrome: An overview and case series"], ["Jacob Vorstman", 2018, "Neuropsychiatric expression and catatonia in 22q11. 2 deletion syndrome: An overview and case series"], ["Erik Boot", 2018, "Neuropsychiatric expression and catatonia in 22q11. 2 deletion syndrome: An overview and case series"], ["Nancy J Butcher", 2018, "Neuropsychiatric expression and catatonia in 22q11. 2 deletion syndrome: An overview and case series"], ["Donna McDonald\u2010McGinn", 2018, "Neuropsychiatric expression and catatonia in 22q11. 2 deletion syndrome: An overview and case series"], ["Anne S Bassett", 2018, "Neuropsychiatric expression and catatonia in 22q11. 2 deletion syndrome: An overview and case series"], ["Max G Griswold", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Mohammed Mehdi Abrar", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Gianna Gayle Herrera Amul", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Austin Douglas Tapp", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Sergei Petrovich Ermakov", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Deena H Al Asfoor", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["David Teye Doku", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Giulia Carreras", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Bianca Calabria", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Pankaj Chaturvedi", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Kairat Davletov", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Aparajita Chattopadhyay", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Michael H Criqui", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Hailemichael Bizuneh", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Manisha Dubey", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Cristina Bosetti", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Liliana G Ciobanu", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Paul I Dargan", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Joseph S Salama", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Maysaa El Sayed Zaki", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Berihun Assefa Dachew", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Jacqueline Castillo Rivas", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Jos\u00e9 Das Neves", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Julio Cesar Campuzano", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Eleonora Dubljanin", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Subhojit Dey", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Peter Bjerregaard", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Guilherme Borges", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Barbora De Courten", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Stephanie RM Zimsen", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Jung-Chen Chang", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Colin Angus", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Hayley D Tymeson", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Vidhya Venkateswaran", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Mohammad H Forouzanfar", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Juan J Carrero", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Euripide F Avokpaho", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Devasahayam J Christopher", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Nicola Luigi Bragazzi", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Dumessa Edessa", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["F\u00e9lix Carvalho", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Estifanos Baye", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Bruce B Duncan", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Sait Mentes Birlik", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Syed Danish Ali", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Fiona J Charlson", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Andrea Farioli", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Ferr\u00e1n Catal\u00e1-L\u00f3pez", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Filipa De Castro", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Lucero Cahuana-Hurtado", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Sheng-Chia Chung", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Sara Conti", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Zahid A Butt", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Don C Des Jarlais", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Holly E Erskine", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Ewerton Cousin", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Ismael R Campos-Nonato", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Meghnath Dhimal", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Addisu Shunu Beyene", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Rupinder Singh Dhaliwal", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Caitlin Hawley", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Louisa Degenhardt", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Hermann Brenner", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Soumyadeeep Bhaumik", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Rafael M Claro", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Hedyeh Ebrahimi", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Charles Birungi", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Rajiv Chowdhury", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Samath Dhamminda Dharmaratne", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Mahbobeh Faramarzi", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Emilie Elisabet Agardh", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Alireza Esteghamati", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Carlos A Casta\u00f1eda-Orjuela", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Gebre Teklemariam Demoz", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Ahmad Daryani", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Kerrie E Doyle", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Jan-Walter De Neve", 2018, "Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016"], ["Paola Imbriani", 2018, "Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy"], ["Tommaso Schirinzi", 2018, "Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy"], ["Giulia Di Lazzaro", 2018, "Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy"], ["Vito Luigi Colona", 2018, "Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy"], ["Simona Scalise", 2018, "Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy"], ["Sergio Bernardini", 2018, "Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy"], ["Giulia Maria Sancesario", 2018, "Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy"], ["Antonio Pisani", 2018, "Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy"], ["Nicola Biagio Mercuri", 2018, "Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy"], ["W Curt LaFrance", 2018, "Current concepts in diagnosis and treatment of functional neurological disorders"], ["Alan Carson", 2018, "Current concepts in diagnosis and treatment of functional neurological disorders"], ["Valerie Voon", 2018, "Current concepts in diagnosis and treatment of functional neurological disorders"], ["Tim Nicholson", 2018, "Current concepts in diagnosis and treatment of functional neurological disorders"], ["Mike Burke", 2018, "Our Favorite Things"], ["Ariel Levy", 2018, "Ataxia\u2010telangiectasia: A review of movement disorders, clinical features and genotype correlations\u2010Addendum"], ["Fabrizio Benedetti", 2018, "Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice"], ["Michel Shamy", 2018, "Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice"], ["Sylvain Houle", 2018, "18 F] AV-1451 binding and postmortem pathology of CBD."], ["Lee Cyn Ang", 2018, "18 F] AV-1451 binding and postmortem pathology of CBD."], ["Sarah Coakeley", 2018, "18 F] AV-1451 binding and postmortem pathology of CBD."], ["Gerard H Jansen", 2018, "18 F] AV-1451 binding and postmortem pathology of CBD."], ["Sang Soo Cho", 2018, "18 F] AV-1451 binding and postmortem pathology of CBD."], ["Marie Vidailhet", 2018, "Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment"], ["Christian Geroin", 2018, "Diagnostic criteria for camptocormia in Parkinson's disease: a consensus-based proposal"], ["Alfredo Berardelli", 2018, "Diagnostic criteria for camptocormia in Parkinson's disease: a consensus-based proposal"], ["Malcolm A Binns", 2018, "Evaluating Drusen and Spectral Domain Optical Coherence Tomography (SDOCT) Retinal Thickness Parameters in Neurodegenerative Disease"], ["Wendy Lou", 2018, "Evaluating Drusen and Spectral Domain Optical Coherence Tomography (SDOCT) Retinal Thickness Parameters in Neurodegenerative Disease"], ["Sandra Black", 2018, "Evaluating Drusen and Spectral Domain Optical Coherence Tomography (SDOCT) Retinal Thickness Parameters in Neurodegenerative Disease"], ["Elena Leontieva", 2018, "Evaluating Drusen and Spectral Domain Optical Coherence Tomography (SDOCT) Retinal Thickness Parameters in Neurodegenerative Disease"], ["Margot Couse", 2018, "Evaluating Drusen and Spectral Domain Optical Coherence Tomography (SDOCT) Retinal Thickness Parameters in Neurodegenerative Disease"], ["Christopher Hudson", 2018, "Evaluating Drusen and Spectral Domain Optical Coherence Tomography (SDOCT) Retinal Thickness Parameters in Neurodegenerative Disease"], ["Anna Santiago", 2018, "Evaluating Drusen and Spectral Domain Optical Coherence Tomography (SDOCT) Retinal Thickness Parameters in Neurodegenerative Disease"], ["Wendy Hatch", 2018, "Evaluating Drusen and Spectral Domain Optical Coherence Tomography (SDOCT) Retinal Thickness Parameters in Neurodegenerative Disease"], ["Richard Cheng", 2018, "Evaluating Drusen and Spectral Domain Optical Coherence Tomography (SDOCT) Retinal Thickness Parameters in Neurodegenerative Disease"], ["Sanjeev Kumar", 2018, "Evaluating Drusen and Spectral Domain Optical Coherence Tomography (SDOCT) Retinal Thickness Parameters in Neurodegenerative Disease"], ["Efrem Mandelcorn", 2018, "Evaluating Drusen and Spectral Domain Optical Coherence Tomography (SDOCT) Retinal Thickness Parameters in Neurodegenerative Disease"], ["Edward Margolin", 2018, "Evaluating Drusen and Spectral Domain Optical Coherence Tomography (SDOCT) Retinal Thickness Parameters in Neurodegenerative Disease"], ["Birgit H\u00f6gl", 2018, "Sleep\u2010related motor and behavioral disorders: Recent advances and new entities"], ["Claudia Trenkwalder", 2018, "Sleep\u2010related motor and behavioral disorders: Recent advances and new entities"], ["Barbara Connolly", 2018, "Smoldering Multiple Myeloma Associated Leukoencephalopathy Presenting with Holmes Tremor, Ataxia, and Pyramidal Syndrome"], ["Camila Catherine Aquino", 2018, "Smoldering Multiple Myeloma Associated Leukoencephalopathy Presenting with Holmes Tremor, Ataxia, and Pyramidal Syndrome"], ["Meike Kasten", 2018, "Clustering of motor and nonmotor traits in leucine\u2010rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study"], ["Carmen Gasca\u2010Salas", 2018, "Clustering of motor and nonmotor traits in leucine\u2010rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study"], ["Birgitt Sch\u00fcle", 2018, "Clustering of motor and nonmotor traits in leucine\u2010rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study"], ["Pettarusp M Wadia", 2018, "Clustering of motor and nonmotor traits in leucine\u2010rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study"], ["Farah Kausar", 2018, "Clustering of motor and nonmotor traits in leucine\u2010rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study"], ["Barbara S Connolly", 2018, "Clustering of motor and nonmotor traits in leucine\u2010rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study"], ["Drew S Kern", 2018, "Clustering of motor and nonmotor traits in leucine\u2010rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study"], ["Elizabeth J Slow", 2018, "Clustering of motor and nonmotor traits in leucine\u2010rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study"], ["Prakash Kumar", 2018, "Clustering of motor and nonmotor traits in leucine\u2010rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study"], ["Jennifer Jain", 2018, "Clustering of motor and nonmotor traits in leucine\u2010rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study"], ["Claustre Pont\u2010Sunyer", 2018, "Clustering of motor and nonmotor traits in leucine\u2010rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study"], ["Taneera Ghate", 2018, "Clustering of motor and nonmotor traits in leucine\u2010rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study"], ["Teri Thomsen", 2018, "Clustering of motor and nonmotor traits in leucine\u2010rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study"], ["Ronald M de Bie", 2018, "Clustering of motor and nonmotor traits in leucine\u2010rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study"], ["Cindy Zadikoff", 2018, "Clustering of motor and nonmotor traits in leucine\u2010rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study"], ["Achinoam Faust\u2010Socher", 2018, "Clustering of motor and nonmotor traits in leucine\u2010rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study"], ["Eduardo Tolosa", 2018, "Clustering of motor and nonmotor traits in leucine\u2010rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study"], ["Gholamali Shahidi", 2018, "Oculogyric crises in PLA2G6 associated neurodegeneration"], ["Farzaneh Vali", 2018, "Oculogyric crises in PLA2G6 associated neurodegeneration"], ["William A Gahl", 2018, "Oculogyric crises in PLA2G6 associated neurodegeneration"], ["Babak Behnam", 2018, "Oculogyric crises in PLA2G6 associated neurodegeneration"], ["Kelly Mills", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Satoshi Kaneko", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Fr\u00e9d\u00e9ric Bourdain", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Annick Vogels", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Boris Dufournet", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Olivier Colin", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Matthew J Barrett", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Nigel M Williams", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Perrine Charles", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Karine Nguyen", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Annika Plate", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Brian D Berman", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Sean Udow", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Michel Borg", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Ann Swillen", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Sophie Drapier", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Jan Booij", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Ania M Fiksinski", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Claudia Perandones", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Teodor Danaila", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Elfi Vergaelen", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Aur\u00e9lia Jacquette", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Kin Y Mok", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Nicholas W Wood", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Kristien Clerinx", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Eug\u00e9nie Mutez", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Paolo Prontera", 2018, "Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11. 2"], ["Christine Allen", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Oliver Jerome Brady", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Mate Car", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Jamal Yearwood", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Rosario C\u00e1rdenas", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Suzanne L Barker-Collo", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Laith J Abu-Raddad", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Kayvan Bozorgmehr", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Mahmoud A Alomari", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Till B\u00e4rnighausen", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Tomi F Akinyemiju", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Gabrielle Britton", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Nahla Anber", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Netsanet Abera Asseffa", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Animut Alebel Ayalew", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Faris Hasan Al Lami", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Euripide Frinel G Arthur Avokpaho", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Mohammed I Albittar", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Khalid A Altirkawi", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Derbew Fikadu Berhe", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Eduardo Bernab\u00e9", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Robert Steven Bernstein", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Aliasghar Ahmad Kiadaliri", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Valdelaine EM Ara\u00fajo", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Stan Biryukov", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Krishna Kumar Aryal", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Mengistu Mitiku Ashebir", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Deena Alasfoor", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Madhu S Atteraya", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Julian Chalek", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Tambe Betrand Ayuk", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Olatunji Adetokunboh", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Daisy MX Abreu", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Peter Azzopardi", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Tesfay Mehari Atey", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Paurvi Bhatt", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Juan Jesus Carrero", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Rajaa Al-Raddadi", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Felix Carvalho", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Hsing-Yi Chang", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Ian W Bolliger", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Kaylin Bolt", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Ismael Ricardo Campos-Nonato", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Traolach S Brugha", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Josip Car", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Kelly Cercy", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Ryan M Barber", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Syed M Aljunid", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["James R Bennett", 2018, "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global \u2026"], ["Cahill Leah Kozloff Nicole", 2018, "Original quantitative research-Canadian trends in opioid-related mortality and disability from opioid use disorder from 1990 to 2014 through the lens of the Global Burden of \u2026"], ["J Lang Justin", 2018, "Original quantitative research-Canadian trends in opioid-related mortality and disability from opioid use disorder from 1990 to 2014 through the lens of the Global Burden of \u2026"], ["M Orpana Heather", 2018, "Original quantitative research-Canadian trends in opioid-related mortality and disability from opioid use disorder from 1990 to 2014 through the lens of the Global Burden of \u2026"], ["Halverson Jessica Baxi Maulik", 2018, "Original quantitative research-Canadian trends in opioid-related mortality and disability from opioid use disorder from 1990 to 2014 through the lens of the Global Burden of \u2026"], ["Patten Scott Alam Samiah", 2018, "Original quantitative research-Canadian trends in opioid-related mortality and disability from opioid use disorder from 1990 to 2014 through the lens of the Global Burden of \u2026"], ["Mateusz Zurowski", 2018, "Expectation-Based Functional Symptom Therapy for the Inpatient Management of Paroxysmal Functional Dystonia"], ["Mario Estevez", 2018, "Beat-to-Beat Heart Rate Variability is Increased in Leucine-rich Repeat Kinase 2-associated Parkinson's Disease"], ["Naomi Visanji", 2018, "Beat-to-Beat Heart Rate Variability is Increased in Leucine-rich Repeat Kinase 2-associated Parkinson's Disease"], ["Birgitt Schuele", 2018, "Beat-to-Beat Heart Rate Variability is Increased in Leucine-rich Repeat Kinase 2-associated Parkinson's Disease"], ["Samuel Goldman", 2018, "Beat-to-Beat Heart Rate Variability is Increased in Leucine-rich Repeat Kinase 2-associated Parkinson's Disease"], ["Herbert Jelinek", 2018, "Beat-to-Beat Heart Rate Variability is Increased in Leucine-rich Repeat Kinase 2-associated Parkinson's Disease"], ["Claudia Carricarte Naranjo", 2018, "Beat-to-Beat Heart Rate Variability is Increased in Leucine-rich Repeat Kinase 2-associated Parkinson's Disease"], ["Andres Machado", 2018, "Beat-to-Beat Heart Rate Variability is Increased in Leucine-rich Repeat Kinase 2-associated Parkinson's Disease"], ["Lazaro Sanchez-Rodriguez", 2018, "Beat-to-Beat Heart Rate Variability is Increased in Leucine-rich Repeat Kinase 2-associated Parkinson's Disease"], ["David Cornforth", 2018, "Beat-to-Beat Heart Rate Variability is Increased in Leucine-rich Repeat Kinase 2-associated Parkinson's Disease"], ["Scott Patten", 2018, "Canadian trends in opioid-related mortality and disability from opioid use disorder from 1990 to 2014 through the lens of the Global Burden of Disease Study."], ["Leah Cahill", 2018, "Canadian trends in opioid-related mortality and disability from opioid use disorder from 1990 to 2014 through the lens of the Global Burden of Disease Study."], ["Howard Morrison", 2018, "Canadian trends in opioid-related mortality and disability from opioid use disorder from 1990 to 2014 through the lens of the Global Burden of Disease Study."], ["Maulik Baxi", 2018, "Canadian trends in opioid-related mortality and disability from opioid use disorder from 1990 to 2014 through the lens of the Global Burden of Disease Study."], ["Leonardo Lopiano", 2018, "Functional neurological disorders in Parkinson disease"], ["Melissa Jill Nirenberg", 2018, "Functional neurological disorders in Parkinson disease"], ["Nutan Sharma", 2018, "Functional neurological disorders in Parkinson disease"], ["Jennifer E Vaughan", 2018, "Functional neurological disorders in Parkinson disease"], ["X Yu Xin", 2018, "Functional neurological disorders in Parkinson disease"], ["Andrew P Duker", 2018, "Functional neurological disorders in Parkinson disease"], ["Christopher Stephen", 2018, "Functional neurological disorders in Parkinson disease"], ["Cara Jacob", 2018, "Functional neurological disorders in Parkinson disease"], ["Bettina Balint", 2018, "Functional neurological disorders in Parkinson disease"], ["Alberto Romagnolo", 2018, "Functional neurological disorders in Parkinson disease"], ["Benjamin D Wissel", 2018, "Functional neurological disorders in Parkinson disease"], ["Danielle Chin", 2018, "Functional neurological disorders in Parkinson disease"], ["Lilia Lovera", 2018, "Functional neurological disorders in Parkinson disease"], ["Jana Huang", 2018, "Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson\u2019s disease"], ["Steve M Callaghan", 2018, "Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson\u2019s disease"], ["Kwang Soo Kim", 2018, "Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson\u2019s disease"], ["Michael G Schlossmacher", 2018, "Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson\u2019s disease"], ["Laura Trinkle-Mulcahy", 2018, "Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson\u2019s disease"], ["Paul C Marcogliese", 2018, "Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson\u2019s disease"], ["David S Park", 2018, "Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson\u2019s disease"], ["Elizabeth Abdel-Messih", 2018, "Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson\u2019s disease"], ["Ruth S Slack", 2018, "Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson\u2019s disease"], ["Jungwoo Yang", 2018, "Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson\u2019s disease"], ["Virginia Resende", 2018, "Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson\u2019s disease"], ["Esther Cubo", 2018, "A 21\u2010Year Retrospective Study of the Toronto Western Hospital Deep Brain Stimulation Cohort"], ["Sara Calvo", 2018, "A 21\u2010Year Retrospective Study of the Toronto Western Hospital Deep Brain Stimulation Cohort"], ["David F Tang-Wai", 2018, "Emotion detection deficits and decreased empathy in patients with Alzheimer\u2019s disease and Parkinson\u2019s disease affect caregiver mood and burden"], ["Maria Martinez", 2018, "Emotion detection deficits and decreased empathy in patients with Alzheimer\u2019s disease and Parkinson\u2019s disease affect caregiver mood and burden"], ["Cassandra J Anor", 2018, "Emotion detection deficits and decreased empathy in patients with Alzheimer\u2019s disease and Parkinson\u2019s disease affect caregiver mood and burden"], ["Maria C Tartaglia", 2018, "Emotion detection deficits and decreased empathy in patients with Alzheimer\u2019s disease and Parkinson\u2019s disease affect caregiver mood and burden"], ["Adam Boxer", 2018, "Efficacy and safety of BIIB092 in patients with progressive supranuclear palsy: PASSPORT phase 2 study design (P6. 073)"], ["G\u00fcnter H\u00f6glinger", 2018, "Efficacy and safety of BIIB092 in patients with progressive supranuclear palsy: PASSPORT phase 2 study design (P6. 073)"], ["Tatsuhiko Yuasa", 2018, "Efficacy and safety of BIIB092 in patients with progressive supranuclear palsy: PASSPORT phase 2 study design (P6. 073)"], ["Michael Grundman", 2018, "Efficacy and safety of BIIB092 in patients with progressive supranuclear palsy: PASSPORT phase 2 study design (P6. 073)"], ["Tien Dam", 2018, "Efficacy and safety of BIIB092 in patients with progressive supranuclear palsy: PASSPORT phase 2 study design (P6. 073)"], ["Jean-Christophe Corvol", 2018, "Efficacy and safety of BIIB092 in patients with progressive supranuclear palsy: PASSPORT phase 2 study design (P6. 073)"], ["Clifford Bechtold", 2018, "Efficacy and safety of BIIB092 in patients with progressive supranuclear palsy: PASSPORT phase 2 study design (P6. 073)"], ["Irfan Qureshi", 2018, "Efficacy and safety of BIIB092 in patients with progressive supranuclear palsy: PASSPORT phase 2 study design (P6. 073)"], ["Eva Schaeffer", 2018, "Validation of the MDS Clinical Diagnostic Criteria for Parkinson\u2019s Disease (S3. 001)"], ["Silvia Rios Romenets", 2018, "Validation of the MDS Clinical Diagnostic Criteria for Parkinson\u2019s Disease (S3. 001)"], ["Ronald Postuma", 2018, "Validation of the MDS Clinical Diagnostic Criteria for Parkinson\u2019s Disease (S3. 001)"], ["Christopher Goetz", 2018, "Validation of the MDS Clinical Diagnostic Criteria for Parkinson\u2019s Disease (S3. 001)"], ["Ian Bledsoe", 2018, "Validation of the MDS Clinical Diagnostic Criteria for Parkinson\u2019s Disease (S3. 001)"], ["Anthony Feinstein", 2018, "Neurostimulation for Functional Weakness: A Longitudinal Evaluation of Cortical Neurophysiology (P2. 181)"], ["Reina Isayama", 2018, "Neurostimulation for Functional Weakness: A Longitudinal Evaluation of Cortical Neurophysiology (P2. 181)"], ["Gaayathiri Jegatheeswaran", 2018, "Neurostimulation for Functional Weakness: A Longitudinal Evaluation of Cortical Neurophysiology (P2. 181)"], ["Matthew J Burke", 2018, "Neurostimulation for Functional Weakness: A Longitudinal Evaluation of Cortical Neurophysiology (P2. 181)"], ["Carolyn Gunraj", 2018, "Neurostimulation for Functional Weakness: A Longitudinal Evaluation of Cortical Neurophysiology (P2. 181)"], ["Michael J Strong", 2018, "Targeted next-generation sequencing and bioinformatics pipeline to evaluate genetic determinants of constitutional disease"], ["Henian Cao", 2018, "Targeted next-generation sequencing and bioinformatics pipeline to evaluate genetic determinants of constitutional disease"], ["Ming Zhang", 2018, "Targeted next-generation sequencing and bioinformatics pipeline to evaluate genetic determinants of constitutional disease"], ["Mahdi Ghani", 2018, "Targeted next-generation sequencing and bioinformatics pipeline to evaluate genetic determinants of constitutional disease"], ["Lemuel Racacho", 2018, "Targeted next-generation sequencing and bioinformatics pipeline to evaluate genetic determinants of constitutional disease"], ["Ekaterina Rogaeva", 2018, "Targeted next-generation sequencing and bioinformatics pipeline to evaluate genetic determinants of constitutional disease"], ["John Turnbull", 2018, "Targeted next-generation sequencing and bioinformatics pipeline to evaluate genetic determinants of constitutional disease"], ["Sali MK Farhan", 2018, "Targeted next-generation sequencing and bioinformatics pipeline to evaluate genetic determinants of constitutional disease"], ["Morris Freedman", 2018, "Targeted next-generation sequencing and bioinformatics pipeline to evaluate genetic determinants of constitutional disease"], ["John F Robinson", 2018, "Targeted next-generation sequencing and bioinformatics pipeline to evaluate genetic determinants of constitutional disease"], ["Christine Sato", 2018, "Targeted next-generation sequencing and bioinformatics pipeline to evaluate genetic determinants of constitutional disease"], ["Robert A Hegele", 2018, "Targeted next-generation sequencing and bioinformatics pipeline to evaluate genetic determinants of constitutional disease"], ["Lorne Zinman", 2018, "Targeted next-generation sequencing and bioinformatics pipeline to evaluate genetic determinants of constitutional disease"], ["Carmela Tartaglia", 2018, "Targeted next-generation sequencing and bioinformatics pipeline to evaluate genetic determinants of constitutional disease"], ["Rick Swartz", 2018, "Targeted next-generation sequencing and bioinformatics pipeline to evaluate genetic determinants of constitutional disease"], ["Allison A Dilliott", 2018, "Targeted next-generation sequencing and bioinformatics pipeline to evaluate genetic determinants of constitutional disease"], ["Sandra E Black", 2018, "Targeted next-generation sequencing and bioinformatics pipeline to evaluate genetic determinants of constitutional disease"], ["Eric Liang", 2018, "Targeted next-generation sequencing and bioinformatics pipeline to evaluate genetic determinants of constitutional disease"], ["Adam D McIntyre", 2018, "Targeted next-generation sequencing and bioinformatics pipeline to evaluate genetic determinants of constitutional disease"], ["Elizabeth Finger", 2018, "Targeted next-generation sequencing and bioinformatics pipeline to evaluate genetic determinants of constitutional disease"], ["Dennis E Bulman", 2018, "Targeted next-generation sequencing and bioinformatics pipeline to evaluate genetic determinants of constitutional disease"], ["Luc L\u00e9ger", 2018, "Making a case for cardiorespiratory fitness surveillance among children and youth"], ["Ian Janssen", 2018, "Making a case for cardiorespiratory fitness surveillance among children and youth"], ["Jonatan R Ruiz", 2018, "Making a case for cardiorespiratory fitness surveillance among children and youth"], ["Veronica Poitras", 2018, "Systematic review of the relationship between 20 m shuttle run performance and health indicators among children and youth"], ["Jinhee Kim", 2018, "[18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP."], ["Pablo Rusjan", 2018, "[18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP."], ["Christine Ghadery", 2018, "[18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP."], ["Yuko Koshimori", 2018, "[18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP."], ["Sapna Rawal", 2018, "CLIPPERS: A Treatable Cause of Spastic Ataxia"], ["Maria Eliza Freitas", 2018, "Linaclotide and prucalopride for management of constipation in patients with parkinsonism"], ["Abdullah Alqaraawi", 2018, "Linaclotide and prucalopride for management of constipation in patients with parkinsonism"], ["Louis WC Liu", 2018, "Linaclotide and prucalopride for management of constipation in patients with parkinsonism"], ["Farzad Sina", 2018, "Action myoclonus and seizure in Kufor\u2010Rakeb syndrome"], ["Elahe Elahi", 2018, "Action myoclonus and seizure in Kufor\u2010Rakeb syndrome"], ["Jose Bras", 2018, "Action myoclonus and seizure in Kufor\u2010Rakeb syndrome"], ["John Hardy", 2018, "Action myoclonus and seizure in Kufor\u2010Rakeb syndrome"], ["Saadet Mercimek-Andrews", 2018, "Infantile-onset hand dystonia with intellectual disability: clues to ARX mutations"], ["David G Munoz", 2018, "Lymphatic vasculature in human dural superior sagittal sinus: implications for neurodegenerative proteinopathies"], ["Tim Olds", 2018, "International variability in 20 m shuttle run performance in children and youth: who are the fittest from a 50-country comparison? A systematic literature review with pooling \u2026"], ["Mojgan Hodaie", 2018, "Pallidal deep brain stimulation modulates cortical excitability and plasticity"], ["Kaviraja Udupa", 2018, "Pallidal deep brain stimulation modulates cortical excitability and plasticity"], ["Suneil K Kalia", 2018, "Pallidal deep brain stimulation modulates cortical excitability and plasticity"], ["Utpal Saha", 2018, "Pallidal deep brain stimulation modulates cortical excitability and plasticity"], ["Carolyn A Gunraj", 2018, "Pallidal deep brain stimulation modulates cortical excitability and plasticity"], ["Nicolas Phielipp", 2018, "Pallidal deep brain stimulation modulates cortical excitability and plasticity"], ["Elena Moro", 2018, "Pallidal deep brain stimulation modulates cortical excitability and plasticity"], ["Sang Jin Kim", 2018, "Pallidal deep brain stimulation modulates cortical excitability and plasticity"], ["Zhen Ni", 2018, "Pallidal deep brain stimulation modulates cortical excitability and plasticity"], ["Soumya Ghosh", 2018, "Pallidal deep brain stimulation modulates cortical excitability and plasticity"], ["Darrin J Lee", 2018, "Pallidal deep brain stimulation modulates cortical excitability and plasticity"], ["Andres M Lozano", 2018, "Pallidal deep brain stimulation modulates cortical excitability and plasticity"], ["Guido Rohrer", 2018, "[18F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy"], ["Nobuyuki Okamura", 2018, "[18F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy"], ["Georg N\u00fcbling", 2018, "[18F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy"], ["Julia Sauerbeck", 2018, "[18F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy"], ["Peter Bartenstein", 2018, "[18F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy"], ["Lawrence Golbe", 2018, "[18F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy"], ["Sonja Sch\u00f6necker", 2018, "[18F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy"], ["Adrian Danek", 2018, "[18F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy"], ["Franziska Vettermann", 2018, "[18F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy"], ["Matthias Brendel", 2018, "[18F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy"], ["Simon Lindner", 2018, "[18F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy"], ["Joachim Havla", 2018, "[18F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy"], ["Katsutoshi Furukawa", 2018, "[18F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy"], ["Christian Zach", 2018, "[18F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy"], ["Janusch Blautzik", 2018, "[18F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy"], ["Aiko Ishiki", 2018, "[18F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy"], ["Axel Rominger", 2018, "[18F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy"], ["Kai B\u00f6tzel", 2018, "[18F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy"], ["Grant Tomkinson", 2018, "Kids\u2019 fitness is improving, but they still aren\u2019t as fit as their parents were"], ["E Wolfe Phillips", 2018, "Other PHAC publications"], ["JJ Lang", 2018, "Other PHAC publications"], ["HM Orpana", 2018, "Other PHAC publications"], ["Max A Little", 2018, "Investigating voice as a biomarker for leucine-rich repeat kinase 2-associated Parkinson\u2019s disease"], ["Athanasios Tsanas", 2018, "Investigating voice as a biomarker for leucine-rich repeat kinase 2-associated Parkinson\u2019s disease"], ["Amaal AlDakheel", 2018, "Investigating voice as a biomarker for leucine-rich repeat kinase 2-associated Parkinson\u2019s disease"], ["Achinoam Faust-Socher", 2018, "Investigating voice as a biomarker for leucine-rich repeat kinase 2-associated Parkinson\u2019s disease"], ["Siddharth Arora", 2018, "Investigating voice as a biomarker for leucine-rich repeat kinase 2-associated Parkinson\u2019s disease"], ["Carmen Gasca-Salas", 2018, "Investigating voice as a biomarker for leucine-rich repeat kinase 2-associated Parkinson\u2019s disease"], ["Zahra Shirzadi", 2018, "Brain tissue pulsatility is related to clinical features of Parkinson's disease"], ["Bradley J MacIntosh", 2018, "Brain tissue pulsatility is related to clinical features of Parkinson's disease"], ["Sarah Duff-Canning", 2018, "Brain tissue pulsatility is related to clinical features of Parkinson's disease"], ["Arron W Metcalfe", 2018, "Brain tissue pulsatility is related to clinical features of Parkinson's disease"], ["George Tomlinson", 2018, "Actigraphy detects greater intra-individual variability during gait in non-manifesting LRRK2 mutation carriers"], ["Margarita Pondal", 2018, "Actigraphy detects greater intra-individual variability during gait in non-manifesting LRRK2 mutation carriers"], ["Andrew S Lim", 2018, "Actigraphy detects greater intra-individual variability during gait in non-manifesting LRRK2 mutation carriers"], ["Ivan Kok Seng Yap", 2018, "Altered gut microbiome and metabolome in patients with multiple system atrophy."], ["Shen\u2010Yang Lim", 2018, "Altered gut microbiome and metabolome in patients with multiple system atrophy."], ["Hoi Sen Yong", 2018, "Altered gut microbiome and metabolome in patients with multiple system atrophy."], ["Yong Qi Tan", 2018, "Altered gut microbiome and metabolome in patients with multiple system atrophy."], ["Chun Wie Chong", 2018, "Altered gut microbiome and metabolome in patients with multiple system atrophy."], ["Cindy Shuan Ju Teh", 2018, "Altered gut microbiome and metabolome in patients with multiple system atrophy."], ["Sze Looi Song", 2018, "Altered gut microbiome and metabolome in patients with multiple system atrophy."], ["Mun Fai Loke", 2018, "Altered gut microbiome and metabolome in patients with multiple system atrophy."], ["James C Eliassen", 2018, "Impaired emotion processing in functional (psychogenic) tremor: a functional magnetic resonance imaging study"], ["Jennifer Vannest", 2018, "Impaired emotion processing in functional (psychogenic) tremor: a functional magnetic resonance imaging study"], ["Jane B Allendorfer", 2018, "Impaired emotion processing in functional (psychogenic) tremor: a functional magnetic resonance imaging study"], ["Thomas Maloney", 2018, "Impaired emotion processing in functional (psychogenic) tremor: a functional magnetic resonance imaging study"], ["Jerzy P Szaflarski", 2018, "Impaired emotion processing in functional (psychogenic) tremor: a functional magnetic resonance imaging study"], ["Matthew M Norris", 2018, "Impaired emotion processing in functional (psychogenic) tremor: a functional magnetic resonance imaging study"], ["Erin Neefus", 2018, "Impaired emotion processing in functional (psychogenic) tremor: a functional magnetic resonance imaging study"], ["Galit Kleiner", 2018, "Educational needs and considerations for a visual educational tool to discuss Parkinson's disease"], ["Douglas E Hobson", 2018, "Educational needs and considerations for a visual educational tool to discuss Parkinson's disease"], ["M Stamelou", 2017, "Which clinical features predict progressive supranuclear palsy pathology? A clinicopathological study on 437 autopsy cases and a literature review"], ["A Pantelyat", 2017, "Which clinical features predict progressive supranuclear palsy pathology? A clinicopathological study on 437 autopsy cases and a literature review"], ["K Josephs", 2017, "Which clinical features predict progressive supranuclear palsy pathology? A clinicopathological study on 437 autopsy cases and a literature review"], ["J Van Swieten", 2017, "Which clinical features predict progressive supranuclear palsy pathology? A clinicopathological study on 437 autopsy cases and a literature review"], ["E Gelpi", 2017, "Which clinical features predict progressive supranuclear palsy pathology? A clinicopathological study on 437 autopsy cases and a literature review"], ["C Nilsson", 2017, "Which clinical features predict progressive supranuclear palsy pathology? A clinicopathological study on 437 autopsy cases and a literature review"], ["W Meissner", 2017, "Which clinical features predict progressive supranuclear palsy pathology? A clinicopathological study on 437 autopsy cases and a literature review"], ["G Hoeglinger", 2017, "Which clinical features predict progressive supranuclear palsy pathology? A clinicopathological study on 437 autopsy cases and a literature review"], ["T Arzberger", 2017, "Which clinical features predict progressive supranuclear palsy pathology? A clinicopathological study on 437 autopsy cases and a literature review"], ["C Troakes", 2017, "Which clinical features predict progressive supranuclear palsy pathology? A clinicopathological study on 437 autopsy cases and a literature review"], ["U Mueller", 2017, "Which clinical features predict progressive supranuclear palsy pathology? A clinicopathological study on 437 autopsy cases and a literature review"], ["C Kurz", 2017, "Which clinical features predict progressive supranuclear palsy pathology? A clinicopathological study on 437 autopsy cases and a literature review"], ["A Rajput", 2017, "Which clinical features predict progressive supranuclear palsy pathology? A clinicopathological study on 437 autopsy cases and a literature review"], ["Y Bordelon", 2017, "Which clinical features predict progressive supranuclear palsy pathology? A clinicopathological study on 437 autopsy cases and a literature review"], ["G Respondek", 2017, "Which clinical features predict progressive supranuclear palsy pathology? A clinicopathological study on 437 autopsy cases and a literature review"], ["D Irwin", 2017, "Which clinical features predict progressive supranuclear palsy pathology? A clinicopathological study on 437 autopsy cases and a literature review"], ["Jordana Compagnone", 2017, "Imaging biomarkers in Parkinson\u2019s disease and Parkinsonian syndromes: current and emerging concepts"], ["Richard I Aviv", 2017, "Imaging biomarkers in Parkinson\u2019s disease and Parkinsonian syndromes: current and emerging concepts"], ["Usman Saeed", 2017, "Imaging biomarkers in Parkinson\u2019s disease and Parkinsonian syndromes: current and emerging concepts"], ["James B Koprich", 2017, "AAV1/2-induced overexpression of A53T-\u03b1-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a \u2026"], ["Jonathan M Brotchie", 2017, "AAV1/2-induced overexpression of A53T-\u03b1-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a \u2026"], ["Akua A Karikari", 2017, "AAV1/2-induced overexpression of A53T-\u03b1-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a \u2026"], ["Chi Wang Ip", 2017, "AAV1/2-induced overexpression of A53T-\u03b1-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a \u2026"], ["Jens Volkmann", 2017, "AAV1/2-induced overexpression of A53T-\u03b1-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a \u2026"], ["Laura-Christin Klaus", 2017, "AAV1/2-induced overexpression of A53T-\u03b1-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a \u2026"], ["Michael Dale", 2017, "International normative 20 m shuttle run values from 1 142 026 children and youth representing 50 countries"], ["Allana G LeBlanc", 2017, "International normative 20 m shuttle run values from 1 142 026 children and youth representing 50 countries"], ["Silke Appel-Cresswell", 2017, "Caffeine as symptomatic treatment for Parkinson disease (Caf\u00e9-PD): A randomized trial"], ["Julius Anang", 2017, "Caffeine as symptomatic treatment for Parkinson disease (Caf\u00e9-PD): A randomized trial"], ["Amelie Pelletier", 2017, "Caffeine as symptomatic treatment for Parkinson disease (Caf\u00e9-PD): A randomized trial"], ["Adriana Moro", 2017, "Caffeine as symptomatic treatment for Parkinson disease (Caf\u00e9-PD): A randomized trial"], ["Sarah Furtado", 2017, "Caffeine as symptomatic treatment for Parkinson disease (Caf\u00e9-PD): A randomized trial"], ["Lawrence Joseph", 2017, "Caffeine as symptomatic treatment for Parkinson disease (Caf\u00e9-PD): A randomized trial"], ["Douglas Hobson", 2017, "Caffeine as symptomatic treatment for Parkinson disease (Caf\u00e9-PD): A randomized trial"], ["Mariana Moscovich", 2017, "Caffeine as symptomatic treatment for Parkinson disease (Caf\u00e9-PD): A randomized trial"], ["Andrew Borys", 2017, "Caffeine as symptomatic treatment for Parkinson disease (Caf\u00e9-PD): A randomized trial"], ["Benzi Kluger", 2017, "Fatigue in Parkinson's disease: report from a multidisciplinary symposium (vol 2, 15025, 2016)"], ["Lauren B Krupp", 2017, "Fatigue in Parkinson's disease: report from a multidisciplinary symposium (vol 2, 15025, 2016)"], ["Christopher P Fagundes", 2017, "Fatigue in Parkinson's disease: report from a multidisciplinary symposium (vol 2, 15025, 2016)"], ["Anne Newbould", 2017, "Fatigue in Parkinson's disease: report from a multidisciplinary symposium (vol 2, 15025, 2016)"], ["Jao-Shin Lou", 2017, "Fatigue in Parkinson's disease: report from a multidisciplinary symposium (vol 2, 15025, 2016)"], ["Laura Marsh", 2017, "Fatigue in Parkinson's disease: report from a multidisciplinary symposium (vol 2, 15025, 2016)"], ["James C Beck", 2017, "Fatigue in Parkinson's disease: report from a multidisciplinary symposium (vol 2, 15025, 2016)"], ["Karen Herlofson", 2017, "Fatigue in Parkinson's disease: report from a multidisciplinary symposium (vol 2, 15025, 2016)"], ["Kelvin L Chou", 2017, "Fatigue in Parkinson's disease: report from a multidisciplinary symposium (vol 2, 15025, 2016)"], ["Gracia Clark", 2017, "Fatigue in Parkinson's disease: report from a multidisciplinary symposium (vol 2, 15025, 2016)"], ["Anne\u2011Catherine Vijverman", 2017, "Progressive Supranuclear Palsy, Corticobasal Degeneration, and the Frontal Cortex"], ["Aristotle Voineskos", 2017, "INTERACTION OF THE INPP5K GENE AND SERUM URIC ACID PREDICT NIGROSTRIATAL DEGENERATION IN PARKINSON'S DISEASE: A GENOME-WIDE INTERACTION STUDY"], ["Shokufeh Sadaghiani", 2017, "INTERACTION OF THE INPP5K GENE AND SERUM URIC ACID PREDICT NIGROSTRIATAL DEGENERATION IN PARKINSON'S DISEASE: A GENOME-WIDE INTERACTION STUDY"], ["M Mallar Chakravarty", 2017, "INTERACTION OF THE INPP5K GENE AND SERUM URIC ACID PREDICT NIGROSTRIATAL DEGENERATION IN PARKINSON'S DISEASE: A GENOME-WIDE INTERACTION STUDY"], ["Tina Roostaei", 2017, "INTERACTION OF THE INPP5K GENE AND SERUM URIC ACID PREDICT NIGROSTRIATAL DEGENERATION IN PARKINSON'S DISEASE: A GENOME-WIDE INTERACTION STUDY"], ["Arash Nazeri", 2017, "INTERACTION OF THE INPP5K GENE AND SERUM URIC ACID PREDICT NIGROSTRIATAL DEGENERATION IN PARKINSON'S DISEASE: A GENOME-WIDE INTERACTION STUDY"], ["George T Mandybur", 2017, "Deconstructing normal pressure hydrocephalus: ventriculomegaly as early sign of neurodegeneration"], ["Gustavo A Da Prat", 2017, "Deconstructing normal pressure hydrocephalus: ventriculomegaly as early sign of neurodegeneration"], ["Charles D Smith", 2017, "Deconstructing normal pressure hydrocephalus: ventriculomegaly as early sign of neurodegeneration"], ["Federico Rodriguez\u2010Porcel", 2017, "Deconstructing normal pressure hydrocephalus: ventriculomegaly as early sign of neurodegeneration"], ["Michela Rosso", 2017, "Deconstructing normal pressure hydrocephalus: ventriculomegaly as early sign of neurodegeneration"], ["Johnna L Devoto", 2017, "Deconstructing normal pressure hydrocephalus: ventriculomegaly as early sign of neurodegeneration"], ["Tobias B\u00e4umer", 2017, "Alcohol improves cerebellar learning deficit in myoclonus\u2013dystonia: A clinical and electrophysiological investigation"], ["Elisa Werner", 2017, "Alcohol improves cerebellar learning deficit in myoclonus\u2013dystonia: A clinical and electrophysiological investigation"], ["Norbert Br\u00fcggemann", 2017, "Alcohol improves cerebellar learning deficit in myoclonus\u2013dystonia: A clinical and electrophysiological investigation"], ["Anne Weissbach", 2017, "Alcohol improves cerebellar learning deficit in myoclonus\u2013dystonia: A clinical and electrophysiological investigation"], ["Sebastian L\u00f6ns", 2017, "Alcohol improves cerebellar learning deficit in myoclonus\u2013dystonia: A clinical and electrophysiological investigation"], ["Kirsten E Zeuner", 2017, "Alcohol improves cerebellar learning deficit in myoclonus\u2013dystonia: A clinical and electrophysiological investigation"], ["Vera Tadic", 2017, "Alcohol improves cerebellar learning deficit in myoclonus\u2013dystonia: A clinical and electrophysiological investigation"], ["Alexander M\u00fcnchau", 2017, "Alcohol improves cerebellar learning deficit in myoclonus\u2013dystonia: A clinical and electrophysiological investigation"], ["Dagmar Timmann", 2017, "Alcohol improves cerebellar learning deficit in myoclonus\u2013dystonia: A clinical and electrophysiological investigation"], ["Sinem Tunc", 2017, "Alcohol improves cerebellar learning deficit in myoclonus\u2013dystonia: A clinical and electrophysiological investigation"], ["Marc R Del Bigio", 2017, "Progressive ataxia and palatal tremor: Two autopsy cases of a novel tauopathy"], ["Andrew F Gao", 2017, "Progressive ataxia and palatal tremor: Two autopsy cases of a novel tauopathy"], ["Maryam Al\u2010Murshed", 2017, "Progressive ataxia and palatal tremor: Two autopsy cases of a novel tauopathy"], ["MJ Nirenberg", 2017, "Functional neurological features in Parkinson disease: a multicenter case-control study"], ["A Levy", 2017, "Functional neurological features in Parkinson disease: a multicenter case-control study"], ["C Jacob", 2017, "Functional neurological features in Parkinson disease: a multicenter case-control study"], ["F Morgante", 2017, "Functional neurological features in Parkinson disease: a multicenter case-control study"], ["BD Wissel", 2017, "Functional neurological features in Parkinson disease: a multicenter case-control study"], ["L Lovera", 2017, "Functional neurological features in Parkinson disease: a multicenter case-control study"], ["JE Vaughan", 2017, "Functional neurological features in Parkinson disease: a multicenter case-control study"], ["B Balint", 2017, "Functional neurological features in Parkinson disease: a multicenter case-control study"], ["AK Dwivedi", 2017, "Functional neurological features in Parkinson disease: a multicenter case-control study"], ["K LaFaver", 2017, "Functional neurological features in Parkinson disease: a multicenter case-control study"], ["N Sharma", 2017, "Functional neurological features in Parkinson disease: a multicenter case-control study"], ["L Lopiano", 2017, "Functional neurological features in Parkinson disease: a multicenter case-control study"], ["A Merola", 2017, "Functional neurological features in Parkinson disease: a multicenter case-control study"], ["K Bhatia", 2017, "Functional neurological features in Parkinson disease: a multicenter case-control study"], ["AP Duker", 2017, "Functional neurological features in Parkinson disease: a multicenter case-control study"], ["C Stephen", 2017, "Functional neurological features in Parkinson disease: a multicenter case-control study"], ["AJ Espay", 2017, "Functional neurological features in Parkinson disease: a multicenter case-control study"], ["D Chin", 2017, "Functional neurological features in Parkinson disease: a multicenter case-control study"], ["A Romagnolo", 2017, "Functional neurological features in Parkinson disease: a multicenter case-control study"], ["JC Rothwell", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["S Przedborski", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["AM Lozano", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["Stephane Lehericy", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["H Bergman", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["Christoph Klein", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["CW Olanow", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["AHV Schapira", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["J William Langston", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["CM Tanner", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["E Bezard", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["M Rodriguez\u2010Violante", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["AJ Stoessl", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["M Hallett", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["DJ Brooks", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["MR DeLong", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["P Calabresi", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["David Burn", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["S Fahn", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["DG Standaert", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["GW Ross", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["DJ Surmeier", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["E Tolosa", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["Glenda Margaret Halliday", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["RB Postuma", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["CG Goetz", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["JH Kordower", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["K Marek", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["Vincenzo Bonifati", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["JA Obeso", 2017, "Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy"], ["Said Razme", 2017, "Tremor\u2010Dominant Pantothenate Kinase\u2010associated Neurodegeneration"], ["Niloufar Yousefi", 2017, "Tremor\u2010Dominant Pantothenate Kinase\u2010associated Neurodegeneration"], ["Madeleine Harris", 2017, "Positron emission tomography imaging of tau pathology in progressive supranuclear palsy"], ["Alan Wilson", 2017, "Positron emission tomography imaging of tau pathology in progressive supranuclear palsy"], ["David Vaillancourt", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Adrian J Ivinson", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Trevor Robbins", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Marta Marquis-Sayagues", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Caroline Williams-Gray", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Kara Page", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Joseph J Locascio", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Alexis Brice", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Anand Viswanathan", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Zhixiang Liao", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Sarah Mason", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Tom Foltynie", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Anne-Marie Wills", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Jacobus J van Hilten", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Albert Y Hung", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Suzanne Lesage", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Steven Greenberg", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Vladislav Petyuk", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Graziella Mangone", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["James Gusella", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Ganqiang Liu", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Deborah Blacker", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Andreas Hartmann", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Roger Barker", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Alice Chen-Plotkin", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Clemens R Scherzer", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Lucette Lacomblez", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Dwight German", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Alberto Ascherio", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Bernard Ravina", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Florence Cormier-Dequaire", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["John H Growdon", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Gabriel Stalberg", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Mark W Albers", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Maria Alora-Palli", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Lewis R Sudarsky", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Anne-Marie Bonnet", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["U Shivraj Sohur", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Sophie Winder-Rhodes", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Bradford Dickerson", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Olivier Rascol", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Dubois Bowman", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Caroline M Tanner", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["E Tessa Hedley-Whyte", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Stephen N Gomperts", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Ira Shoulson", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Alain Mallet", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Trey Hedden", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Gemma Cummins", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Matthew Frosch", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Jing Zhang", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Val\u00e9rie Mesnage", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Alice W Flaherty", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Khadija Tahiri", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Michael T Hayes", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Jessica Kloppenburg", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Andy West", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Stephan Klebe", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Anat Stemmer-Rachaminov", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Reisa Sperling", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Teresa Gomez-Isla", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Daly Franco", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Roy Alcalay", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Olivia Okereke", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Nicte I Mejia", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Bradley T Hyman", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Vikram Khurana", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Roger Albin", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Brendon Boot", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Johan Marinus", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Ana Trisini-Lipsanopoulos", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Scott McGinnis", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Clemens Scherzer", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Alexis Elbaz", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Gad Marshall", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Franck Durif", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Rachel Saunders-Pullman", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Chizoba C Umeh", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Haining Li", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Cecilia Bonnet", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Iris E Jansen", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Ted Dawson", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Pascal Derkinderen", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Jonathan Evans", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Kyle Burke", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Sylvie Forlani", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Dennis J Selkoe", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Peter Heutink", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Jean-Philippe Brandel", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Richard Dewey", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Thomas Yi", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Christine Brefel-Courbon", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Fabienne Ory-Magne", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Aaron Koenig", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["Fernando Pico", 2017, "Prediction of cognition in Parkinson's disease with a clinical\u2013genetic score: a longitudinal analysis of nine cohorts"], ["C Barton", 2017, "Warm up"], ["P Henriksson", 2017, "Warm up"], ["MP Reiman", 2017, "Warm up"], ["H Henriksson", 2017, "Warm up"], ["SR Stevens", 2017, "Warm up"], ["A Grimaldi", 2017, "Warm up"], ["EM Roos", 2017, "Warm up"], ["A Spreco", 2017, "Warm up"], ["S Mayes", 2017, "Warm up"], ["M Davison", 2017, "Warm up"], ["MS Tremblay", 2017, "Warm up"], ["D Medina", 2017, "Warm up"], ["BD Zumbo", 2017, "Warm up"], ["KM Crossley", 2017, "Warm up"], ["GR Tomkinson", 2017, "Warm up"], ["T Pizzari", 2017, "Warm up"], ["AG Schache", 2017, "Warm up"], ["P Tynelius", 2017, "Warm up"], ["PR Lawrenson", 2017, "Warm up"], ["N Balague", 2017, "Warm up"], ["FB Ortega", 2017, "Warm up"], ["M Scholes", 2017, "Warm up"], ["R Pol", 2017, "Warm up"], ["LA L\u00e9ger", 2017, "Warm up"], ["S Mutch", 2017, "Warm up"], ["BB Forster", 2017, "Warm up"], ["A Parker", 2017, "Warm up"], ["AI Semciw", 2017, "Warm up"], ["P Glasgow", 2017, "Warm up"], ["D Taylor", 2017, "Warm up"], ["CR Snell", 2017, "Warm up"], ["JL Kemp", 2017, "Warm up"], ["J Ekstrand", 2017, "Warm up"], ["W Parker", 2017, "Warm up"], ["MG King", 2017, "Warm up"], ["J Stevens", 2017, "Warm up"], ["SJH Biddle", 2017, "Warm up"], ["N Shrestha", 2017, "Warm up"], ["J Grgic", 2017, "Warm up"], ["H Podnar", 2017, "Warm up"], ["JA Bennie", 2017, "Warm up"], ["K Thorborg", 2017, "Warm up"], ["JJ Heerey", 2017, "Warm up"], ["MA Risberg", 2017, "Warm up"], ["TE Davenport", 2017, "Warm up"], ["N Armstrong", 2017, "Warm up"], ["J Welsman", 2017, "Warm up"], ["D Nabhan", 2017, "Warm up"], ["M Freke", 2017, "Warm up"], ["TS Olds", 2017, "Warm up"], ["LHH Ingelsrud", 2017, "Warm up"], ["JM VanNess", 2017, "Warm up"], ["G Wiesner", 2017, "Warm up"], ["J Windt", 2017, "Warm up"], ["R Hristovski", 2017, "Warm up"], ["JR Ruiz", 2017, "Warm up"], ["Z Pedisic", 2017, "Warm up"], ["Jin-Tai Yu", 2017, "New diagnostics and therapeutics for progressive supranuclear palsy"], ["Adam L Boxer", 2017, "New diagnostics and therapeutics for progressive supranuclear palsy"], ["James Kennedy", 2017, "A PROSPECTIVE OBSERVATIONAL STUDY INVESTIGATING CLINICAL RESPONSE TO CHOLINESTERASE INHIBITORS AND ASSOCIATION WITH CEREBRAL PERFUSION"], ["Joyce Lee", 2017, "A PROSPECTIVE OBSERVATIONAL STUDY INVESTIGATING CLINICAL RESPONSE TO CHOLINESTERASE INHIBITORS AND ASSOCIATION WITH CEREBRAL PERFUSION"], ["Henri JMM Mutsaerts", 2017, "A PROSPECTIVE OBSERVATIONAL STUDY INVESTIGATING CLINICAL RESPONSE TO CHOLINESTERASE INHIBITORS AND ASSOCIATION WITH CEREBRAL PERFUSION"], ["Nathan Herrmann", 2017, "A PROSPECTIVE OBSERVATIONAL STUDY INVESTIGATING CLINICAL RESPONSE TO CHOLINESTERASE INHIBITORS AND ASSOCIATION WITH CEREBRAL PERFUSION"], ["Julian Li", 2017, "A PROSPECTIVE OBSERVATIONAL STUDY INVESTIGATING CLINICAL RESPONSE TO CHOLINESTERASE INHIBITORS AND ASSOCIATION WITH CEREBRAL PERFUSION"], ["A Aldakheel", 2017, "Unilateral peduncolopontine nucleus stimulation in progressive supranuclear palsy: A randomized trial"], ["C Hamani", 2017, "Unilateral peduncolopontine nucleus stimulation in progressive supranuclear palsy: A randomized trial"], ["C Zadikoff", 2017, "Unilateral peduncolopontine nucleus stimulation in progressive supranuclear palsy: A randomized trial"], ["E Moro", 2017, "Unilateral peduncolopontine nucleus stimulation in progressive supranuclear palsy: A randomized trial"], ["E Scelzo", 2017, "Unilateral peduncolopontine nucleus stimulation in progressive supranuclear palsy: A randomized trial"], ["YY Poon", 2017, "Unilateral peduncolopontine nucleus stimulation in progressive supranuclear palsy: A randomized trial"], ["Judith Maria Anthofer", 2017, "Distance between active electrode contacts and dentatorubrothalamic tract in patients with habituation of stimulation effect of deep brain stimulation in essential tremor"], ["Max Lange", 2017, "Distance between active electrode contacts and dentatorubrothalamic tract in patients with habituation of stimulation effect of deep brain stimulation in essential tremor"], ["Claudia Fellner", 2017, "Distance between active electrode contacts and dentatorubrothalamic tract in patients with habituation of stimulation effect of deep brain stimulation in essential tremor"], ["Eva Rothenfusser", 2017, "Distance between active electrode contacts and dentatorubrothalamic tract in patients with habituation of stimulation effect of deep brain stimulation in essential tremor"], ["Juergen Schlaier", 2017, "Distance between active electrode contacts and dentatorubrothalamic tract in patients with habituation of stimulation effect of deep brain stimulation in essential tremor"], ["Kathrin Steib", 2017, "Distance between active electrode contacts and dentatorubrothalamic tract in patients with habituation of stimulation effect of deep brain stimulation in essential tremor"], ["Alexander Brawanski", 2017, "Distance between active electrode contacts and dentatorubrothalamic tract in patients with habituation of stimulation effect of deep brain stimulation in essential tremor"], ["Gil D Rabinovici", 2017, "Which ante mortem clinical features predict progressive supranuclear palsy pathology?"], ["Yvette Bordelon", 2017, "Which ante mortem clinical features predict progressive supranuclear palsy pathology?"], ["Huw Morris", 2017, "Which ante mortem clinical features predict progressive supranuclear palsy pathology?"], ["Jean\u2010Christophe Corvol", 2017, "Which ante mortem clinical features predict progressive supranuclear palsy pathology?"], ["Brit Mollenhauer", 2017, "Which ante mortem clinical features predict progressive supranuclear palsy pathology?"], ["Richard Dodel", 2017, "Which ante mortem clinical features predict progressive supranuclear palsy pathology?"], ["Florian Krismer", 2017, "Which ante mortem clinical features predict progressive supranuclear palsy pathology?"], ["Carolin Kurz", 2017, "Which ante mortem clinical features predict progressive supranuclear palsy pathology?"], ["Stefan Lorenzl", 2017, "Which ante mortem clinical features predict progressive supranuclear palsy pathology?"], ["Movement Disorder Society\u2010Endorsed PSP Study Group", 2017, "Which ante mortem clinical features predict progressive supranuclear palsy pathology?"], ["Peter Nestor", 2017, "Which ante mortem clinical features predict progressive supranuclear palsy pathology?"], ["Emma Scelzo", 2017, "Peduncolopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial"], ["Clement Hamani", 2017, "Peduncolopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial"], ["Amaal Aldakheel", 2017, "Peduncolopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial"], ["Yu-Yan Poon", 2017, "Peduncolopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial"], ["I Shoulson", 2017, "Long-term dopamine transporter imaging and clinical effects of the mixed-lineage kinase inhibitor CEP-1347 in the PRECEPT Parkinson Trial"], ["D Oakes", 2017, "Long-term dopamine transporter imaging and clinical effects of the mixed-lineage kinase inhibitor CEP-1347 in the PRECEPT Parkinson Trial"], ["SE Eberly", 2017, "Long-term dopamine transporter imaging and clinical effects of the mixed-lineage kinase inhibitor CEP-1347 in the PRECEPT Parkinson Trial"], ["J Seibyl", 2017, "Long-term dopamine transporter imaging and clinical effects of the mixed-lineage kinase inhibitor CEP-1347 in the PRECEPT Parkinson Trial"], ["M Schwarzschild", 2017, "Long-term dopamine transporter imaging and clinical effects of the mixed-lineage kinase inhibitor CEP-1347 in the PRECEPT Parkinson Trial"], ["C Tanner", 2017, "Long-term dopamine transporter imaging and clinical effects of the mixed-lineage kinase inhibitor CEP-1347 in the PRECEPT Parkinson Trial"], ["K Marder", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["S Goldwurm", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["M Tazir", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["G Riboldazzi", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["C Rieder", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["C Sue", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["K Brockmann", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["J Marti-Masso", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["K Hasegawa", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["C Klein", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["R Saunders-Pullman", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["D Berg", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["R Munhoz", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["R Alcalay", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["J Aasly", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["J Ferreira", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["G Mellick", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["M San Luciano", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["C Meng", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["A Brice", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["E Tan", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["S Bressman", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["J Langston", 2017, "Caffeinated Drinks, LRRK2 Genotype and PD"], ["D Munoz", 2017, "Dural lymphatic vasculature in human superior saggital sinus: The brain drain"], ["N Lobaugh", 2017, "Abnormal spontaneous activity and functional connectivity in patients with Parkinson's disease with anxiety"], ["S Chavez", 2017, "Abnormal spontaneous activity and functional connectivity in patients with Parkinson's disease with anxiety"], ["M Zurowski", 2017, "Abnormal spontaneous activity and functional connectivity in patients with Parkinson's disease with anxiety"], ["Y Koshimori", 2017, "Abnormal spontaneous activity and functional connectivity in patients with Parkinson's disease with anxiety"], ["S Houle", 2017, "Abnormal spontaneous activity and functional connectivity in patients with Parkinson's disease with anxiety"], ["A Strafella", 2017, "Abnormal spontaneous activity and functional connectivity in patients with Parkinson's disease with anxiety"], ["M Criaud", 2017, "Abnormal spontaneous activity and functional connectivity in patients with Parkinson's disease with anxiety"], ["H Sharmarke", 2017, "U-shaped dopamine resting state connectivity response function related to working memory performance in adults with early-stage Parkinson's disease"], ["B MacIntosh", 2017, "U-shaped dopamine resting state connectivity response function related to working memory performance in adults with early-stage Parkinson's disease"], ["S Duff-Canning", 2017, "U-shaped dopamine resting state connectivity response function related to working memory performance in adults with early-stage Parkinson's disease"], ["D Long", 2017, "U-shaped dopamine resting state connectivity response function related to working memory performance in adults with early-stage Parkinson's disease"], ["A Metcalfe", 2017, "U-shaped dopamine resting state connectivity response function related to working memory performance in adults with early-stage Parkinson's disease"], ["S Udow", 2017, "U-shaped dopamine resting state connectivity response function related to working memory performance in adults with early-stage Parkinson's disease"], ["Z Shirzadi", 2017, "U-shaped dopamine resting state connectivity response function related to working memory performance in adults with early-stage Parkinson's disease"], ["M Masellis", 2017, "U-shaped dopamine resting state connectivity response function related to working memory performance in adults with early-stage Parkinson's disease"], ["S Eberly", 2017, "Prognostic relevance and predictive ability of data-driven PD subtypes in the longitudinal and biomarker studies in Parkinson's disease (LABS-PD)"], ["D Grimes", 2017, "Prognostic relevance and predictive ability of data-driven PD subtypes in the longitudinal and biomarker studies in Parkinson's disease (LABS-PD)"], ["T Mestre", 2017, "Prognostic relevance and predictive ability of data-driven PD subtypes in the longitudinal and biomarker studies in Parkinson's disease (LABS-PD)"], ["T Johnston", 2017, "Using cognitive computing to identify compounds with antidyskinetic potential for Parkinson's disease"], ["E Argentinis", 2017, "Using cognitive computing to identify compounds with antidyskinetic potential for Parkinson's disease"], ["S Ezell", 2017, "Using cognitive computing to identify compounds with antidyskinetic potential for Parkinson's disease"], ["A Lacoste", 2017, "Using cognitive computing to identify compounds with antidyskinetic potential for Parkinson's disease"], ["J Brotchie", 2017, "Using cognitive computing to identify compounds with antidyskinetic potential for Parkinson's disease"], ["S Spangler", 2017, "Using cognitive computing to identify compounds with antidyskinetic potential for Parkinson's disease"], ["A Robertson", 2017, "Cardiac-related pulsatility in white matter is associated with cognitive and motor performance in patients with Parkinson's disease"], ["L Christopher", 2017, "Interactions between amyloid-beta and microglial activation in Parkinson's disease"], ["S Coakeley", 2017, "Interactions between amyloid-beta and microglial activation in Parkinson's disease"], ["C Ghadery", 2017, "Interactions between amyloid-beta and microglial activation in Parkinson's disease"], ["M Harris", 2017, "Interactions between amyloid-beta and microglial activation in Parkinson's disease"], ["J Kim", 2017, "Interactions between amyloid-beta and microglial activation in Parkinson's disease"], ["P Rusjan", 2017, "Interactions between amyloid-beta and microglial activation in Parkinson's disease"], ["R Saunders Pullman", 2017, "Calcium Channel Blocking Drugs and Risk of LRRK2 Parkinson's Disease"], ["W Langston", 2017, "Calcium Channel Blocking Drugs and Risk of LRRK2 Parkinson's Disease"], ["M Korell", 2017, "Calcium Channel Blocking Drugs and Risk of LRRK2 Parkinson's Disease"], ["EK Tan", 2017, "Calcium Channel Blocking Drugs and Risk of LRRK2 Parkinson's Disease"], ["A Moro", 2017, "Caffeine as a treatment for Parkinson's disease: A randomized controlled trial (CafePD)"], ["R Postuma", 2017, "Caffeine as a treatment for Parkinson's disease: A randomized controlled trial (CafePD)"], ["J Anang", 2017, "Caffeine as a treatment for Parkinson's disease: A randomized controlled trial (CafePD)"], ["D Hobson", 2017, "Caffeine as a treatment for Parkinson's disease: A randomized controlled trial (CafePD)"], ["A Borys", 2017, "Caffeine as a treatment for Parkinson's disease: A randomized controlled trial (CafePD)"], ["S Cresswell", 2017, "Caffeine as a treatment for Parkinson's disease: A randomized controlled trial (CafePD)"], ["A Pelletier", 2017, "Caffeine as a treatment for Parkinson's disease: A randomized controlled trial (CafePD)"], ["L Joseph", 2017, "Caffeine as a treatment for Parkinson's disease: A randomized controlled trial (CafePD)"], ["S Furtado", 2017, "Caffeine as a treatment for Parkinson's disease: A randomized controlled trial (CafePD)"], ["M Moscovich", 2017, "Caffeine as a treatment for Parkinson's disease: A randomized controlled trial (CafePD)"], ["A Faust-Socher", 2017, "A quantitative meta-analysis study of Impulse control disorders in patients with and without Parkinson's disease"], ["A Mihaescu", 2017, "A quantitative meta-analysis study of Impulse control disorders in patients with and without Parkinson's disease"], ["S Cho", 2017, "A quantitative meta-analysis study of Impulse control disorders in patients with and without Parkinson's disease"], ["Ewgeni Jakubovski", 2017, "Gilles de la Tourette-Syndrom: Klinik, Ursachen, Therapie"], ["Kirsten R M\u00fcller-Vahl", 2017, "Gilles de la Tourette-Syndrom: Klinik, Ursachen, Therapie"], ["Diony Young", 2017, "A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY\u2010PD III)"], ["Karen Hodgeman", 2017, "A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY\u2010PD III)"], ["Tanya Simuni", 2017, "A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY\u2010PD III)"], ["Rebecca Rockhill", 2017, "A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY\u2010PD III)"], ["Charles Venuto", 2017, "A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY\u2010PD III)"], ["Robert A Hauser", 2017, "A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY\u2010PD III)"], ["Brittany Greco", 2017, "A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY\u2010PD III)"], ["Parkinson Study Group STEADY\u2010PD III Investigators", 2017, "A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY\u2010PD III)"], ["Jillian Lowell", 2017, "A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY\u2010PD III)"], ["Kevin M Biglan", 2017, "A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY\u2010PD III)"], ["Gerard D Schellenberg", 2017, "Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria"], ["John van Swieten", 2017, "Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria"], ["Gil Rabinovici", 2017, "Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria"], ["Leslie Ferguson", 2017, "Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria"], ["Caroline Kurz", 2017, "Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria"], ["Movement Disorder Society\u2013endorsed PSP Study Group", 2017, "Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria"], ["Nadine Knowles", 2017, "Trial of dextromethorphan/quinidine to treat levodopa\u2010induced dyskinesia in Parkinson's disease"], ["John G Nutt", 2017, "Trial of dextromethorphan/quinidine to treat levodopa\u2010induced dyskinesia in Parkinson's disease"], ["Leonard Verhagen Metman", 2017, "Trial of dextromethorphan/quinidine to treat levodopa\u2010induced dyskinesia in Parkinson's disease"], ["Jo\u00e3o Siffert", 2017, "Trial of dextromethorphan/quinidine to treat levodopa\u2010induced dyskinesia in Parkinson's disease"], ["Matthew Brodsky", 2017, "Trial of dextromethorphan/quinidine to treat levodopa\u2010induced dyskinesia in Parkinson's disease"], ["Laura E Pope", 2017, "Trial of dextromethorphan/quinidine to treat levodopa\u2010induced dyskinesia in Parkinson's disease"], ["Justin Lang", 2017, "Gender Inequality and Sex Differences in 20 Meter Shuttle Run Test Performance across 45 Countries: 2190 Board# 203 June 1 330 PM-500 PM"], ["Taru Manyanga", 2017, "Gender Inequality and Sex Differences in 20 Meter Shuttle Run Test Performance across 45 Countries: 2190 Board# 203 June 1 330 PM-500 PM"], ["Saadet Mercimek-Mahmutoglu", 2017, "Nomenclature of genetic movement disorders: Recommendations of the International Parkinson and Movement Disorder Society task force."], ["Carolyn M Sue", 2017, "Nomenclature of genetic movement disorders: Recommendations of the International Parkinson and Movement Disorder Society task force."], ["Bart P van de Warrenburg", 2017, "Nomenclature of genetic movement disorders: Recommendations of the International Parkinson and Movement Disorder Society task force."], ["Thomas T Warner", 2017, "Nomenclature of genetic movement disorders: Recommendations of the International Parkinson and Movement Disorder Society task force."], ["Lars Bertram", 2017, "Nomenclature of genetic movement disorders: Recommendations of the International Parkinson and Movement Disorder Society task force."], ["Sarah J Tabrizi", 2017, "Nomenclature of genetic movement disorders: Recommendations of the International Parkinson and Movement Disorder Society task force."], ["Alexandra Durr", 2017, "Nomenclature of genetic movement disorders: Recommendations of the International Parkinson and Movement Disorder Society task force."], ["Darius Ebrahimi-Fakhari", 2017, "Nomenclature of genetic movement disorders: Recommendations of the International Parkinson and Movement Disorder Society task force."], ["Birgit Assmann", 2017, "Nomenclature of genetic movement disorders: Recommendations of the International Parkinson and Movement Disorder Society task force."], ["Vladimir Kostic", 2017, "Nomenclature of genetic movement disorders: Recommendations of the International Parkinson and Movement Disorder Society task force."], ["Katja Lohmann", 2017, "Nomenclature of genetic movement disorders: Recommendations of the International Parkinson and Movement Disorder Society task force."], ["Gabriela M Repetto", 2017, "Neuroimaging and clinical features in adults with a 22q11. 2 deletion at risk of Parkinson\u2019s disease"], ["Leigh Christopher", 2017, "Neuroimaging and clinical features in adults with a 22q11. 2 deletion at risk of Parkinson\u2019s disease"], ["Rosemarie Fritsch", 2017, "Neuroimaging and clinical features in adults with a 22q11. 2 deletion at risk of Parkinson\u2019s disease"], ["Eva WC Chow", 2017, "Neuroimaging and clinical features in adults with a 22q11. 2 deletion at risk of Parkinson\u2019s disease"], ["Frank L Silver", 2017, "TARDBP Mutation Presenting as Progressive Hemiplegia"], ["David F Tang\u2010Wai", 2017, "TARDBP Mutation Presenting as Progressive Hemiplegia"], ["Danah Aljaafari", 2017, "Motor phenotype differentiates adult patients with Dravet Syndrome from Lennox-Gastaut Syndrome (P4. 241)"], ["Fabio Nascimento", 2017, "Motor phenotype differentiates adult patients with Dravet Syndrome from Lennox-Gastaut Syndrome (P4. 241)"], ["Lewis Sudarsky", 2017, "Neuropathic Gaucher\u2019s Mutations: Shifting Parkinson\u2019s Into High Gear (S1. 002)"], ["Sami Amr", 2017, "Neuropathic Gaucher\u2019s Mutations: Shifting Parkinson\u2019s Into High Gear (S1. 002)"], ["Jacobus van Hilten", 2017, "Neuropathic Gaucher\u2019s Mutations: Shifting Parkinson\u2019s Into High Gear (S1. 002)"], ["Karen Duong", 2017, "Neuropathic Gaucher\u2019s Mutations: Shifting Parkinson\u2019s Into High Gear (S1. 002)"], ["DIGPD PSG", 2017, "Neuropathic Gaucher\u2019s Mutations: Shifting Parkinson\u2019s Into High Gear (S1. 002)"], ["Mike Nalls", 2017, "Neuropathic Gaucher\u2019s Mutations: Shifting Parkinson\u2019s Into High Gear (S1. 002)"], ["Tom Yi", 2017, "Neuropathic Gaucher\u2019s Mutations: Shifting Parkinson\u2019s Into High Gear (S1. 002)"], ["Iris Jansen", 2017, "Neuropathic Gaucher\u2019s Mutations: Shifting Parkinson\u2019s Into High Gear (S1. 002)"], ["PROPARK PICNICS", 2017, "Neuropathic Gaucher\u2019s Mutations: Shifting Parkinson\u2019s Into High Gear (S1. 002)"], ["Xianjun Dong", 2017, "Neuropathic Gaucher\u2019s Mutations: Shifting Parkinson\u2019s Into High Gear (S1. 002)"], ["Samantha J Hutten", 2017, "Neuropathic Gaucher\u2019s Mutations: Shifting Parkinson\u2019s Into High Gear (S1. 002)"], ["CamPaIGN HBS", 2017, "Neuropathic Gaucher\u2019s Mutations: Shifting Parkinson\u2019s Into High Gear (S1. 002)"], ["Grace S Bhudhikanok", 2017, "Heart rate variability in leucine\u2010rich repeat kinase 2\u2010associated Parkinson's disease"], ["Kaviraj Udupa", 2017, "Heart rate variability in leucine\u2010rich repeat kinase 2\u2010associated Parkinson's disease"], ["Sam Kim", 2017, "Heart rate variability in leucine\u2010rich repeat kinase 2\u2010associated Parkinson's disease"], ["Ruksana Azhu Valappil", 2017, "Heart rate variability in leucine\u2010rich repeat kinase 2\u2010associated Parkinson's disease"], ["Samuel M Goldman", 2017, "Heart rate variability in leucine\u2010rich repeat kinase 2\u2010associated Parkinson's disease"], ["Glenda M Halliday", 2017, "Parkinson disease"], ["Anette-Eleonore Schrag", 2017, "Parkinson disease"], ["David K Simon", 2017, "Biomarker\u2010driven phenotyping in Parkinson's disease: A translational missing link in disease\u2010modifying clinical trials"], ["Roberto Erro", 2017, "Biomarker\u2010driven phenotyping in Parkinson's disease: A translational missing link in disease\u2010modifying clinical trials"], ["Hubert H Fernandez", 2017, "Biomarker\u2010driven phenotyping in Parkinson's disease: A translational missing link in disease\u2010modifying clinical trials"], ["Eric A Macklin", 2017, "Biomarker\u2010driven phenotyping in Parkinson's disease: A translational missing link in disease\u2010modifying clinical trials"], ["Daniel Woo", 2017, "Biomarker\u2010driven phenotyping in Parkinson's disease: A translational missing link in disease\u2010modifying clinical trials"], ["Alice Chen\u2010Plotkin", 2017, "Biomarker\u2010driven phenotyping in Parkinson's disease: A translational missing link in disease\u2010modifying clinical trials"], ["R Chen", 2017, "Neurostimulation for the treatment of functional neurological disorders: Novel therapeutic strategy or placebo effect?"], ["MJ Burke", 2017, "Neurostimulation for the treatment of functional neurological disorders: Novel therapeutic strategy or placebo effect?"], ["P Gros", 2017, "Neurostimulation for the treatment of functional neurological disorders: Novel therapeutic strategy or placebo effect?"], ["A Feinstein", 2017, "Neurostimulation for the treatment of functional neurological disorders: Novel therapeutic strategy or placebo effect?"], ["Danielle M Andrade", 2017, "Adult motor phenotype differentiates Dravet syndrome from Lennox\u2010Gastaut syndrome and links SCN1A to early onset parkinsonian features"], ["F\u00e1bio A Nascimento", 2017, "Adult motor phenotype differentiates Dravet syndrome from Lennox\u2010Gastaut syndrome and links SCN1A to early onset parkinsonian features"], ["Stephen Strother", 2017, "The Ontario neurodegenerative disease research initiative (ONDRI)"], ["Sean Symons", 2017, "The Ontario neurodegenerative disease research initiative (ONDRI)"], ["ONDRI Investigators", 2017, "The Ontario neurodegenerative disease research initiative (ONDRI)"], ["Douglas P Munoz", 2017, "The Ontario neurodegenerative disease research initiative (ONDRI)"], ["Chris Hudson", 2017, "The Ontario neurodegenerative disease research initiative (ONDRI)"], ["Manuel Montero-Odasso", 2017, "The Ontario neurodegenerative disease research initiative (ONDRI)"], ["Peter W Kleinstiver", 2017, "The Ontario neurodegenerative disease research initiative (ONDRI)"], ["Barry Greenberg", 2017, "The Ontario neurodegenerative disease research initiative (ONDRI)"], ["Richard H Swartz", 2017, "The Ontario neurodegenerative disease research initiative (ONDRI)"], ["David A Grimes", 2017, "The Ontario neurodegenerative disease research initiative (ONDRI)"], ["Dale Corbett", 2017, "The Ontario neurodegenerative disease research initiative (ONDRI)"], ["William E McIlroy", 2017, "The Ontario neurodegenerative disease research initiative (ONDRI)"], ["Robert Bartha", 2017, "The Ontario neurodegenerative disease research initiative (ONDRI)"], ["Paula M McLaughlin", 2017, "The Ontario neurodegenerative disease research initiative (ONDRI)"], ["Lining Guo", 2017, "Metabolomic biomarkers as strong correlates of Parkinson disease progression"], ["Jia Li", 2017, "Metabolomic biomarkers as strong correlates of Parkinson disease progression"], ["Peter A LeWitt", 2017, "Metabolomic biomarkers as strong correlates of Parkinson disease progression"], ["Peggy Auinger", 2017, "Metabolomic biomarkers as strong correlates of Parkinson disease progression"], ["Mei Lu", 2017, "Metabolomic biomarkers as strong correlates of Parkinson disease progression"], ["Antonio Strafella", 2017, "Amyloid-beta deposition effects microglial activation in Parkinson's disease"], ["Karen Marder", 2017, "Occupational pesticide exposure and penetrance of LRRK2 Parkinson's disease (PD)"], ["Monica Korell", 2017, "Occupational pesticide exposure and penetrance of LRRK2 Parkinson's disease (PD)"], ["George Mellick", 2017, "Occupational pesticide exposure and penetrance of LRRK2 Parkinson's disease (PD)"], ["Marta San Luciano", 2017, "Occupational pesticide exposure and penetrance of LRRK2 Parkinson's disease (PD)"], ["Joaquim Ferreira", 2017, "Occupational pesticide exposure and penetrance of LRRK2 Parkinson's disease (PD)"], ["Cheryl Chen Meng", 2017, "Occupational pesticide exposure and penetrance of LRRK2 Parkinson's disease (PD)"], ["Susan Bressman", 2017, "Occupational pesticide exposure and penetrance of LRRK2 Parkinson's disease (PD)"], ["Meriem Tazir", 2017, "Occupational pesticide exposure and penetrance of LRRK2 Parkinson's disease (PD)"], ["AF Gao", 2017, "Progressive ataxia and palatal tremor: 2 autopsy cases of a novel tauopathy"], ["M Del Bigio", 2017, "Progressive ataxia and palatal tremor: 2 autopsy cases of a novel tauopathy"], ["DG Munoz", 2017, "Progressive ataxia and palatal tremor: 2 autopsy cases of a novel tauopathy"], ["M Al-Murshed", 2017, "Progressive ataxia and palatal tremor: 2 autopsy cases of a novel tauopathy"], ["A Socher", 2017, "Progressive ataxia and palatal tremor: 2 autopsy cases of a novel tauopathy"], ["J\u00fcrgen Sperner", 2017, "Alternating hemiplegia of childhood as a new presentation of adenylate cyclase 5-mutation-associated disease: a report of two cases"], ["Jens Schallner", 2017, "Alternating hemiplegia of childhood as a new presentation of adenylate cyclase 5-mutation-associated disease: a report of two cases"], ["Karen Gr\u00fctz", 2017, "Alternating hemiplegia of childhood as a new presentation of adenylate cyclase 5-mutation-associated disease: a report of two cases"], ["Ana Westenberger", 2017, "Alternating hemiplegia of childhood as a new presentation of adenylate cyclase 5-mutation-associated disease: a report of two cases"], ["Heike Pawlack", 2017, "Alternating hemiplegia of childhood as a new presentation of adenylate cyclase 5-mutation-associated disease: a report of two cases"], ["Christoph Max", 2017, "Alternating hemiplegia of childhood as a new presentation of adenylate cyclase 5-mutation-associated disease: a report of two cases"], ["Juliane Spiegler", 2017, "Alternating hemiplegia of childhood as a new presentation of adenylate cyclase 5-mutation-associated disease: a report of two cases"], ["Victor SC Fung", 2017, "Alternating hemiplegia of childhood as a new presentation of adenylate cyclase 5-mutation-associated disease: a report of two cases"], ["Aloysius Domingo", 2017, "Alternating hemiplegia of childhood as a new presentation of adenylate cyclase 5-mutation-associated disease: a report of two cases"], ["Andrea A K\u00fchn", 2017, "Alternating hemiplegia of childhood as a new presentation of adenylate cyclase 5-mutation-associated disease: a report of two cases"], ["Gabriele Gillessen-Kaesbach", 2017, "Alternating hemiplegia of childhood as a new presentation of adenylate cyclase 5-mutation-associated disease: a report of two cases"], ["Corneliu C Luca", 2017, "Asymmetric neuromodulation of motor circuits in Parkinson's disease: the role of subthalamic deep brain stimulation"], ["Alessandra Gorgulho", 2017, "Asymmetric neuromodulation of motor circuits in Parkinson's disease: the role of subthalamic deep brain stimulation"], ["Antonio De Salles", 2017, "Asymmetric neuromodulation of motor circuits in Parkinson's disease: the role of subthalamic deep brain stimulation"], ["William McIlroy", 2017, "Motor phenotype in neurodegenerative disorders: gait and balance platform study design protocol for the Ontario Neurodegenerative Research Initiative (ONDRI)"], ["Frederico Pieruccini-Faria", 2017, "Motor phenotype in neurodegenerative disorders: gait and balance platform study design protocol for the Ontario Neurodegenerative Research Initiative (ONDRI)"], ["Jason Laramie", 2017, "A Bayesian mathematical model of motor and cognitive outcomes in Parkinson\u2019s disease"], ["Paul McDonagh", 2017, "A Bayesian mathematical model of motor and cognitive outcomes in Parkinson\u2019s disease"], ["Andrew Singleton", 2017, "A Bayesian mathematical model of motor and cognitive outcomes in Parkinson\u2019s disease"], ["Diane Wuest", 2017, "A Bayesian mathematical model of motor and cognitive outcomes in Parkinson\u2019s disease"], ["Iya Khalil", 2017, "A Bayesian mathematical model of motor and cognitive outcomes in Parkinson\u2019s disease"], ["Ajay Verma", 2017, "A Bayesian mathematical model of motor and cognitive outcomes in Parkinson\u2019s disease"], ["Boris Hayete", 2017, "A Bayesian mathematical model of motor and cognitive outcomes in Parkinson\u2019s disease"], ["Bruce Church", 2017, "A Bayesian mathematical model of motor and cognitive outcomes in Parkinson\u2019s disease"], ["Karl Runge", 2017, "A Bayesian mathematical model of motor and cognitive outcomes in Parkinson\u2019s disease"], ["Daniele Merico", 2017, "Whole-genome sequencing suggests mechanisms for 22q11. 2 deletion-associated Parkinson\u2019s disease"], ["Stephen W Scherer", 2017, "Whole-genome sequencing suggests mechanisms for 22q11. 2 deletion-associated Parkinson\u2019s disease"], ["Christian R Marshall", 2017, "Whole-genome sequencing suggests mechanisms for 22q11. 2 deletion-associated Parkinson\u2019s disease"], ["Lucas Ogura", 2017, "Whole-genome sequencing suggests mechanisms for 22q11. 2 deletion-associated Parkinson\u2019s disease"], ["Mehdi Zarrei", 2017, "Whole-genome sequencing suggests mechanisms for 22q11. 2 deletion-associated Parkinson\u2019s disease"], ["Kapil D Sethi", 2017, "Will New Genetic Techniques Like Exome Sequencing Obviate the Need for Clinical Expertise? No"], ["Kelly Aminian", 2017, "Fatigue in Parkinson's disease: The contribution of cerebral metabolic changes"], ["Crystal Li", 2017, "Fatigue in Parkinson's disease: The contribution of cerebral metabolic changes"], ["Jean-Philippe Langevin", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Philip A Starr", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Aysegul Gunduz", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Alon Y Mogilner", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Michael Pourfar", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Bryan T Klassen", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Darin D Dougherty", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Greg A Gerhardt", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Coralie De Hemptine", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Harrison C Walker", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Joohi Jimenez-Shahed", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["James J Giordano", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Peter J Rossi", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Francisco A Ponce", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Jonathan B Shute", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Peter A Silburn", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Michael Oh", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Paul B Rosenberg", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Wissam Deeb", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Umer Akbar", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Marvin A Rossi", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Howard J Chizeck", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Aparna Wagle Shukla", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Craig Van Horne", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Damiaan Deny", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Helen M Bronte-Stewart", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Timothy Denison", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Helen S Mayberg", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Gwenn S Smith", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Jill L Ostrem", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["David Rowell", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Christopher R Butson", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Michael S Okun", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Warren M Grill", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Jack W Judy", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Kelly D Foote", 2016, "Proceedings of the fourth annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Mark Jacobs", 2016, "Disrupted nodal and hub organization account for brain network abnormalities in Parkinson\u2019s disease"], ["Sang-Soo Cho", 2016, "Disrupted nodal and hub organization account for brain network abnormalities in Parkinson\u2019s disease"], ["Marion Criaud", 2016, "Disrupted nodal and hub organization account for brain network abnormalities in Parkinson\u2019s disease"], ["Romina Mizrahi", 2016, "Disrupted nodal and hub organization account for brain network abnormalities in Parkinson\u2019s disease"], ["Jonathan Elofson", 2016, "Progression of brain atrophy in PSP and CBS over 6 months and 1 year"], ["Phi Luong", 2016, "Progression of brain atrophy in PSP and CBS over 6 months and 1 year"], ["John Kornak", 2016, "Progression of brain atrophy in PSP and CBS over 6 months and 1 year"], ["Priyanka Bhatt", 2016, "Progression of brain atrophy in PSP and CBS over 6 months and 1 year"], ["Joel H Kramer", 2016, "Progression of brain atrophy in PSP and CBS over 6 months and 1 year"], ["Shubir Dutt", 2016, "Progression of brain atrophy in PSP and CBS over 6 months and 1 year"], ["Suneth Attygalle", 2016, "Progression of brain atrophy in PSP and CBS over 6 months and 1 year"], ["Bradford C Dickerson", 2016, "Progression of brain atrophy in PSP and CBS over 6 months and 1 year"], ["Hilary W Heuer", 2016, "Progression of brain atrophy in PSP and CBS over 6 months and 1 year"], ["Howard J Rosen", 2016, "Progression of brain atrophy in PSP and CBS over 6 months and 1 year"], ["Lisa Voltarelli", 2016, "Progression of brain atrophy in PSP and CBS over 6 months and 1 year"], ["Richard J Binney", 2016, "Progression of brain atrophy in PSP and CBS over 6 months and 1 year"], ["Clifford R Jack", 2016, "Progression of brain atrophy in PSP and CBS over 6 months and 1 year"], ["Gabe A Marx", 2016, "Progression of brain atrophy in PSP and CBS over 6 months and 1 year"], ["Dana Waltzman", 2016, "Progression of brain atrophy in PSP and CBS over 6 months and 1 year"], ["Norbert Schuff", 2016, "Progression of brain atrophy in PSP and CBS over 6 months and 1 year"], ["Scott M McGinnis", 2016, "Progression of brain atrophy in PSP and CBS over 6 months and 1 year"], ["Bruce L Miller", 2016, "Progression of brain atrophy in PSP and CBS over 6 months and 1 year"], ["SS Amr", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["DJ Selkoe", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["K Duong", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["V Khurana", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["X Dong", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["D Franco", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["S Mason", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["NI Mejia", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["AJ Ivinson", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["JH Growdon", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["J Marinus", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["MT Hayes", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["D Grabli", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["M Vidailhet", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["T Yi", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["L Lacomblez", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["F Durif", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["A Elbaz", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["S Forlani", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["V Mesnage", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["JJ van Hilten", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["Florence Cormier\u2010Dequaire", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["Z Liao", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["Sophie Winder\u2010Rhodes", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["Caroline H Williams\u2010Gray", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["MA Schwarzschild", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["LR Sudarsky", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["O Rascol", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["A Mallet", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["A Trisini\u2010Lipsanopoulos", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["SN Gomperts", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["G Mangone", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["CC Umeh", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["F Pico", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["J\u2010C Corvol", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["International Genetics of Parkinson Disease Progression (IGPP) Consortium", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["C Scherzer", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["S Lesage", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["AW Flaherty", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["BT Hyman", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["A Hartmann", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["SJ Hutten", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["A\u2010M Wills", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["J\u2010P Brandel", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["K Burke", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["C Bonnet", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["K Tahiri", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["P Derkinderen", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["S Winder\u2010Rhodes", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["G Cummins", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["J Evans", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["S Klebe", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["K Page", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["CH Williams\u2010Gray", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["A\u2010M Bonnet", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["MA Nalls", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["R Barker", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["F Bourdain", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["AY Hung", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["T Foltynie", 2016, "Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's"], ["Joel C Watts", 2016, "\u03b1-Synuclein-based animal models of Parkinson's disease: challenges and opportunities in a new era"], ["Anurag Tandon", 2016, "\u03b1-Synuclein-based animal models of Parkinson's disease: challenges and opportunities in a new era"], ["Camila C Aquino", 2016, "Deep brain stimulation in rare inherited dystonias"], ["Melanie Fallis", 2016, "Deep brain stimulation in rare inherited dystonias"], ["Isabelle Beaulieu-Boire", 2016, "Deep brain stimulation in rare inherited dystonias"], ["Antony E Lang", 2016, "Deep brain stimulation in rare inherited dystonias"], ["Bruno Dubois", 2016, "Abolishing the 1\u2010year rule: How much evidence will be enough?"], ["Parkinson International", 2016, "Reply letter to Jinnah\" Locus pocus\" and Albanese\" Complex dystonia is not a category in the new 2013 consensus classification\": Necessary evolution, no magic!"], ["Robert J Ure", 2016, "Unusual tremor syndromes: know in order to recognise"], ["Sanveer Dhanju", 2016, "Unusual tremor syndromes: know in order to recognise"], ["Michael B Coulthart", 2016, "A case cluster of variant Creutzfeldt-Jakob disease linked to the Kingdom of Saudi Arabia"], ["Pierluigi Gambetti", 2016, "A case cluster of variant Creutzfeldt-Jakob disease linked to the Kingdom of Saudi Arabia"], ["Shireen Qureshi", 2016, "A case cluster of variant Creutzfeldt-Jakob disease linked to the Kingdom of Saudi Arabia"], ["Ermias Belay", 2016, "A case cluster of variant Creutzfeldt-Jakob disease linked to the Kingdom of Saudi Arabia"], ["Joseph Y Abrams", 2016, "A case cluster of variant Creutzfeldt-Jakob disease linked to the Kingdom of Saudi Arabia"], ["Alex Demarsh", 2016, "A case cluster of variant Creutzfeldt-Jakob disease linked to the Kingdom of Saudi Arabia"], ["Michael D Geschwind", 2016, "A case cluster of variant Creutzfeldt-Jakob disease linked to the Kingdom of Saudi Arabia"], ["Lawrence B Schonberger", 2016, "A case cluster of variant Creutzfeldt-Jakob disease linked to the Kingdom of Saudi Arabia"], ["Christos Sidiropoulos", 2016, "Long\u2010term double\u2010blinded unilateral pedunculopontine area stimulation in Parkinson's disease"], ["Yu\u2010Yan Poon", 2016, "Long\u2010term double\u2010blinded unilateral pedunculopontine area stimulation in Parkinson's disease"], ["Sheila Riazi", 2016, "A novel KCNA1 mutation in a family with episodic ataxia and malignant hyperthermia"], ["Michael G Hanna", 2016, "A novel KCNA1 mutation in a family with episodic ataxia and malignant hyperthermia"], ["Natalia Kraeva", 2016, "A novel KCNA1 mutation in a family with episodic ataxia and malignant hyperthermia"], ["Grace Yoon", 2016, "A novel KCNA1 mutation in a family with episodic ataxia and malignant hyperthermia"], ["Heather MacDonald", 2016, "A novel KCNA1 mutation in a family with episodic ataxia and malignant hyperthermia"], ["Roope M\u00e4nnikk\u00f6", 2016, "A novel KCNA1 mutation in a family with episodic ataxia and malignant hyperthermia"], ["Andreea Manole", 2016, "A novel KCNA1 mutation in a family with episodic ataxia and malignant hyperthermia"], ["\u00c1lvaro S\u00e1nchez\u2010Ferro", 2016, "Advances in sensor and wearable technologies for Parkinson's disease"], ["Jochen Klucken", 2016, "Technology in Parkinson's disease: challenges and opportunities"], ["Lothar Krinke", 2016, "Technology in Parkinson's disease: challenges and opportunities"], ["Alice Nieuwboer", 2016, "Technology in Parkinson's disease: challenges and opportunities"], ["Bjoern M Eskofier", 2016, "Technology in Parkinson's disease: challenges and opportunities"], ["Malcolm Horne", 2016, "Technology in Parkinson's disease: challenges and opportunities"], ["Georgia Mitsi", 2016, "Technology in Parkinson's disease: challenges and opportunities"], ["Ralf Reilmann", 2016, "Technology in Parkinson's disease: challenges and opportunities"], ["Fay Horak", 2016, "Technology in Parkinson's disease: challenges and opportunities"], ["Michelle A Burack", 2016, "Technology in Parkinson's disease: challenges and opportunities"], ["Ken Kubota", 2016, "Technology in Parkinson's disease: challenges and opportunities"], ["Jeffery M Hausdorff", 2016, "Technology in Parkinson's disease: challenges and opportunities"], ["Anita Kamondi", 2016, "Technology in Parkinson's disease: challenges and opportunities"], ["Jean\u2010Francois Daneault", 2016, "Technology in Parkinson's disease: challenges and opportunities"], ["Fatta B Nahab", 2016, "Technology in Parkinson's disease: challenges and opportunities"], ["E Ray Dorsey", 2016, "Technology in Parkinson's disease: challenges and opportunities"], ["Catarina Godinho", 2016, "Technology in Parkinson's disease: challenges and opportunities"], ["John M Dean", 2016, "Technology in Parkinson's disease: challenges and opportunities"], ["Joe Giuffrida", 2016, "Technology in Parkinson's disease: challenges and opportunities"], ["Paolo Bonato", 2016, "Technology in Parkinson's disease: challenges and opportunities"], ["Movement Disorders Society Task Force on Technology", 2016, "Technology in Parkinson's disease: challenges and opportunities"], ["Spyros Papapetropoulos", 2016, "Technology in Parkinson's disease: challenges and opportunities"], ["Fabin Han", 2016, "Stem cell therapy for Parkinson's disease"], ["Glenn W Anderson", 2016, "Diagnosis and misdiagnosis of adult neuronal ceroid lipofuscinosis (Kufs disease)"], ["Susan L Cotman", 2016, "Diagnosis and misdiagnosis of adult neuronal ceroid lipofuscinosis (Kufs disease)"], ["Anna P\u0159istoupilov\u00e1", 2016, "Diagnosis and misdiagnosis of adult neuronal ceroid lipofuscinosis (Kufs disease)"], ["Karen L Oliver", 2016, "Diagnosis and misdiagnosis of adult neuronal ceroid lipofuscinosis (Kufs disease)"], ["Sara E Mole", 2016, "Diagnosis and misdiagnosis of adult neuronal ceroid lipofuscinosis (Kufs disease)"], ["Michael S Hildebrand", 2016, "Diagnosis and misdiagnosis of adult neuronal ceroid lipofuscinosis (Kufs disease)"], ["Katherine B Sims", 2016, "Diagnosis and misdiagnosis of adult neuronal ceroid lipofuscinosis (Kufs disease)"], ["Patrick Cossette", 2016, "Diagnosis and misdiagnosis of adult neuronal ceroid lipofuscinosis (Kufs disease)"], ["Stirling Carpenter", 2016, "Diagnosis and misdiagnosis of adult neuronal ceroid lipofuscinosis (Kufs disease)"], ["John A Damiano", 2016, "Diagnosis and misdiagnosis of adult neuronal ceroid lipofuscinosis (Kufs disease)"], ["John F Staropoli", 2016, "Diagnosis and misdiagnosis of adult neuronal ceroid lipofuscinosis (Kufs disease)"], ["Stanislav Kmoch", 2016, "Diagnosis and misdiagnosis of adult neuronal ceroid lipofuscinosis (Kufs disease)"], ["Katherine R Smith", 2016, "Diagnosis and misdiagnosis of adult neuronal ceroid lipofuscinosis (Kufs disease)"], ["Ivana Jedli\u010dkov\u00e1", 2016, "Diagnosis and misdiagnosis of adult neuronal ceroid lipofuscinosis (Kufs disease)"], ["Maxime Cadieux-Dion", 2016, "Diagnosis and misdiagnosis of adult neuronal ceroid lipofuscinosis (Kufs disease)"], ["Samuel F Berkovic", 2016, "Diagnosis and misdiagnosis of adult neuronal ceroid lipofuscinosis (Kufs disease)"], ["David R Urbach", 2016, "Appendectomy in mid and later life and risk of Parkinson's disease: A population\u2010based study"], ["Peter C Austin", 2016, "Appendectomy in mid and later life and risk of Parkinson's disease: A population\u2010based study"], ["Cindy Lau", 2016, "Appendectomy in mid and later life and risk of Parkinson's disease: A population\u2010based study"], ["Jayasudha Vavilla", 2016, "THE IMPORTANCE OF FINDING JOY AND HUMOUR IN CAREGIVING FOR FAMILY CAREGIVERS CARING FOR A PERSON WITH DEMENTIA"], ["Arron WS Metcalfe", 2016, "ELEVATED PHYSIOLOGICAL FLUCTUATIONS IN WHITE MATTER IS RELATED TO DISEASE SEVERITY IN PATIENTS WITH PARKINSON'S DISEASE"], ["Hanad Sharmarke", 2016, "ELEVATED PHYSIOLOGICAL FLUCTUATIONS IN WHITE MATTER IS RELATED TO DISEASE SEVERITY IN PATIENTS WITH PARKINSON'S DISEASE"], ["David Long", 2016, "COGNITIVE PERFORMANCE AND FUNCTIONAL CONNECTIVITY ARE MODULATED BY STRIATAL DOPAMINERGIC DEFICIT IN ADULTS WITH PARKINSON\u2019S DISEASE"], ["Cassandra Jessica Anor", 2016, "CHANGES IN EMOTION DETECTION AND EMPATHY IN ALZHEIMER\u2019S DISEASE AND PARKINSON\u2019S DISEASE AFFECT CARE PARTNER MOOD"], ["Michael R Hayden", 2016, "Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: a pharmacogenetic study"], ["Eli Eyal", 2016, "Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: a pharmacogenetic study"], ["Elijahu Berkovich", 2016, "Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: a pharmacogenetic study"], ["Joseph Levy", 2016, "Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: a pharmacogenetic study"], ["Cheryl Fitzer-Attas", 2016, "Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: a pharmacogenetic study"], ["Maria Tampakeras", 2016, "Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: a pharmacogenetic study"], ["Shannon Collinson", 2016, "Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: a pharmacogenetic study"], ["James L Kennedy", 2016, "Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: a pharmacogenetic study"], ["Amir Tchelet", 2016, "Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: a pharmacogenetic study"], ["ADAGIO investigators", 2016, "Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: a pharmacogenetic study"], ["Victor Abler", 2016, "Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: a pharmacogenetic study"], ["Arun Tiwari", 2016, "Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: a pharmacogenetic study"], ["Iris Grossman", 2016, "Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: a pharmacogenetic study"], ["Jo Knight", 2016, "Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: a pharmacogenetic study"], ["Rom E Eliaz", 2016, "Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: a pharmacogenetic study"], ["Natalie Freeman", 2016, "Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: a pharmacogenetic study"], ["AL-108-231 Investigators", 2016, "Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials"], ["Bruce H Morimoto", 2016, "Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials"], ["Rachelle S Doody", 2016, "Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials"], ["Lon S Schneider", 2016, "Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials"], ["Andrew Lees", 2016, "Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials"], ["Iryna V Lobach", 2016, "Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials"], ["Michael Gold", 2016, "Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials"], ["Jee Bang", 2016, "Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials"], ["David S Knopman", 2016, "Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials"], ["Melissa J Armstrong", 2016, "Augmented Restless Legs Syndrome with Marked Hyperkinesias and Impulsive\u2010Compulsive Behaviors"], ["Carlos H Schenck", 2016, "Augmented Restless Legs Syndrome with Marked Hyperkinesias and Impulsive\u2010Compulsive Behaviors"], ["Lucy M McGarry", 2016, "Deficits in the mimicry of facial expressions in Parkinson's disease"], ["Esztella Vezer", 2016, "Deficits in the mimicry of facial expressions in Parkinson's disease"], ["Frank A Russo", 2016, "Deficits in the mimicry of facial expressions in Parkinson's disease"], ["Steven R Livingstone", 2016, "Deficits in the mimicry of facial expressions in Parkinson's disease"], ["K Gruetz", 2016, "Alternating hemiplegia of childhood (AHC) as a new presentation of adenylate cyclase 5 (ADCY5)-mutation-associated disease: 608"], ["C Max", 2016, "Alternating hemiplegia of childhood (AHC) as a new presentation of adenylate cyclase 5 (ADCY5)-mutation-associated disease: 608"], ["A Domingo", 2016, "Alternating hemiplegia of childhood (AHC) as a new presentation of adenylate cyclase 5 (ADCY5)-mutation-associated disease: 608"], ["A Muenchau", 2016, "Alternating hemiplegia of childhood (AHC) as a new presentation of adenylate cyclase 5 (ADCY5)-mutation-associated disease: 608"], ["A Weissbach", 2016, "Alternating hemiplegia of childhood (AHC) as a new presentation of adenylate cyclase 5 (ADCY5)-mutation-associated disease: 608"], ["A Westenberger", 2016, "Alternating hemiplegia of childhood (AHC) as a new presentation of adenylate cyclase 5 (ADCY5)-mutation-associated disease: 608"], ["J Spiegler", 2016, "Alternating hemiplegia of childhood (AHC) as a new presentation of adenylate cyclase 5 (ADCY5)-mutation-associated disease: 608"], ["J Sperner", 2016, "Alternating hemiplegia of childhood (AHC) as a new presentation of adenylate cyclase 5 (ADCY5)-mutation-associated disease: 608"], ["N Brueggemann", 2016, "Alternating hemiplegia of childhood (AHC) as a new presentation of adenylate cyclase 5 (ADCY5)-mutation-associated disease: 608"], ["J Schallner", 2016, "Alternating hemiplegia of childhood (AHC) as a new presentation of adenylate cyclase 5 (ADCY5)-mutation-associated disease: 608"], ["A Kuehn", 2016, "Alternating hemiplegia of childhood (AHC) as a new presentation of adenylate cyclase 5 (ADCY5)-mutation-associated disease: 608"], ["H Pawlack", 2016, "Alternating hemiplegia of childhood (AHC) as a new presentation of adenylate cyclase 5 (ADCY5)-mutation-associated disease: 608"], ["G Gillessen-Kaesbach", 2016, "Alternating hemiplegia of childhood (AHC) as a new presentation of adenylate cyclase 5 (ADCY5)-mutation-associated disease: 608"], ["V Fung", 2016, "Alternating hemiplegia of childhood (AHC) as a new presentation of adenylate cyclase 5 (ADCY5)-mutation-associated disease: 608"], ["E Slow", 2016, "PET imaging of tau pathology in progressive supranuclear palsy: 1164"], ["A Graff-Guerrero", 2016, "PET imaging of tau pathology in progressive supranuclear palsy: 1164"], ["L Kalia", 2016, "PET imaging of tau pathology in progressive supranuclear palsy: 1164"], ["M Little", 2016, "Investigating voice as a biomarker of LRRK2-associated Parkinson's disease (PD): 662"], ["T Ghate", 2016, "Investigating voice as a biomarker of LRRK2-associated Parkinson's disease (PD): 662"], ["S Arora", 2016, "Investigating voice as a biomarker of LRRK2-associated Parkinson's disease (PD): 662"], ["Corinna Hartmann", 2016, "Launching the movement disorders society genetic mutation database (MDSGene)"], ["Andriy Mashychev", 2016, "Launching the movement disorders society genetic mutation database (MDSGene)"], ["Christina M Lill", 2016, "Launching the movement disorders society genetic mutation database (MDSGene)"], ["Inga Liepelt-Scarfone", 2016, "The new definition and diagnostic criteria of Parkinson's disease"], ["Joseph Friedman", 2016, "Parkinson's disease\u2010related fatigue: A case definition and recommendations for clinical research"], ["Benzi M Kluger", 2016, "Parkinson's disease\u2010related fatigue: A case definition and recommendations for clinical research"], ["Jau\u2010Shin Lou", 2016, "Parkinson's disease\u2010related fatigue: A case definition and recommendations for clinical research"], ["Enrico Opri", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Andre Machado", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Codrin Lungu", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["W Jeff Elias", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Brian H Kopell", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Aparna Shukla", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Coralie de Hemptinne", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["G Karl Steinke", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["P Justin Rossi", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Ludy C Shih", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Alexander I Tr\u00f6ster", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Yagna Pathak", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Jack Judy", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Linda Wilson", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Michele Tagliati", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Rene Molina", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Jonathan Shute", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Kareem A Zaghloul", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Cameron C McIntyre", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Wayne Goodman", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Leopoldo Cendejas-Zaragoza", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Michael D Fox", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Kevin J Otto", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Christopher L Butson", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Karim G Oweiss", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Nicole C Swann", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Craig van Horne", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Nora Vanegas", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Nader Pouratian", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Leonard Verhagen", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Robert E Gross", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Jeffrey Herron", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Ron L Alterman", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Daniel Martinez-Ramirez", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Todd Herrington", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Sameer A Sheth", 2016, "Proceedings of the third annual deep brain stimulation think tank: a review of emerging issues and technologies"], ["Felippe Borlot", 2016, "Antecollis and Levodopa-Responsive Parkinsonism Are Late Features of Dravet Syndrome (P3. 241)"], ["Fasano Alfonso", 2016, "Antecollis and Levodopa-Responsive Parkinsonism Are Late Features of Dravet Syndrome (P3. 241)"], ["Simone Zittel", 2016, "The role of mutations in COL6A3 in isolated dystonia"], ["Sadaf Naz", 2016, "The role of mutations in COL6A3 in isolated dystonia"], ["Eckart Altenm\u00fcller", 2016, "The role of mutations in COL6A3 in isolated dystonia"], ["Alexander Wolters", 2016, "The role of mutations in COL6A3 in isolated dystonia"], ["Julia Graf", 2016, "The role of mutations in COL6A3 in isolated dystonia"], ["Pablo Mir", 2016, "The role of mutations in COL6A3 in isolated dystonia"], ["Hans-Christian Jabusch", 2016, "The role of mutations in COL6A3 in isolated dystonia"], ["Sun Ju Chung", 2016, "The role of mutations in COL6A3 in isolated dystonia"], ["Felix Schlicht", 2016, "The role of mutations in COL6A3 in isolated dystonia"], ["Frauke Hinrichs", 2016, "The role of mutations in COL6A3 in isolated dystonia"], ["Patricia Krause", 2016, "The role of mutations in COL6A3 in isolated dystonia"], ["Marina Svetel", 2016, "The role of mutations in COL6A3 in isolated dystonia"], ["Christoph Kamm", 2016, "The role of mutations in COL6A3 in isolated dystonia"], ["Thora Lohnau", 2016, "The role of mutations in COL6A3 in isolated dystonia"], ["Vladimir S Kostic", 2016, "The role of mutations in COL6A3 in isolated dystonia"], ["Alexander Schmidt", 2016, "The role of mutations in COL6A3 in isolated dystonia"], ["Saadet Mercimek\u2010Mahmutoglu", 2016, "N omenclature of genetic movement disorders: R ecommendations of the international P arkinson and movement disorder society task force"], ["Darius Ebrahimi\u2010Fakhari", 2016, "N omenclature of genetic movement disorders: R ecommendations of the international P arkinson and movement disorder society task force"], ["Sang S Cho", 2016, "Contribution of insula in Parkinson's disease: A quantitative meta\u2010analysis study"], ["Benedicte Ballanger", 2016, "Contribution of insula in Parkinson's disease: A quantitative meta\u2010analysis study"], ["Philippe Boulinguez", 2016, "Contribution of insula in Parkinson's disease: A quantitative meta\u2010analysis study"], ["Mark F Lew", 2016, "Integrated safety of levodopa\u2010carbidopa intestinal gel from prospective clinical trials"], ["John T Slevin", 2016, "Integrated safety of levodopa\u2010carbidopa intestinal gel from prospective clinical trials"], ["Sylvain Chouinard", 2016, "Integrated safety of levodopa\u2010carbidopa intestinal gel from prospective clinical trials"], ["Per Odin", 2016, "Integrated safety of levodopa\u2010carbidopa intestinal gel from prospective clinical trials"], ["Jordan Dubow", 2016, "Integrated safety of levodopa\u2010carbidopa intestinal gel from prospective clinical trials"], ["James T Boyd", 2016, "Integrated safety of levodopa\u2010carbidopa intestinal gel from prospective clinical trials"], ["Weining Z Robieson", 2016, "Integrated safety of levodopa\u2010carbidopa intestinal gel from prospective clinical trials"], ["Krai Chatamra", 2016, "Integrated safety of levodopa\u2010carbidopa intestinal gel from prospective clinical trials"], ["Ramon L Rodriguez", 2016, "Integrated safety of levodopa\u2010carbidopa intestinal gel from prospective clinical trials"], ["Susan Eaton", 2016, "Integrated safety of levodopa\u2010carbidopa intestinal gel from prospective clinical trials"], ["Janet A Benesh", 2016, "Integrated safety of levodopa\u2010carbidopa intestinal gel from prospective clinical trials"], ["David A Stein", 2016, "Integrated safety of levodopa\u2010carbidopa intestinal gel from prospective clinical trials"], ["Nathan Schmulewitz", 2016, "Integrated safety of levodopa\u2010carbidopa intestinal gel from prospective clinical trials"], ["Fabian Klostermann", 2016, "Integrated safety of levodopa\u2010carbidopa intestinal gel from prospective clinical trials"], ["Peter V Draganov", 2016, "Integrated safety of levodopa\u2010carbidopa intestinal gel from prospective clinical trials"], ["A Gupta", 2016, "MRI signs of multiple system atrophy preceding the clinical diagnosis: the case for an imaging-supported probable MSA diagnostic category"], ["TA Mestre", 2016, "MRI signs of multiple system atrophy preceding the clinical diagnosis: the case for an imaging-supported probable MSA diagnostic category"], ["Mark S Moehle", 2016, "Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers"], ["Kyle B Fraser", 2016, "Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers"], ["Roy N Alcalay", 2016, "Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers"], ["Andrew B West", 2016, "Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers"], ["Sarah Duff Canning", 2016, "Progression of neuropsychiatric and cognitive features due to exons 2 to 5 deletion in the epsilon-sarcoglycan gene: a case report"], ["Tay Kay Yaw", 2016, "Clozapine in parkinsonian rest tremor: a review of outcomes, adverse reactions, and possible mechanisms of action"], ["Gustavo B Vincos", 2016, "Learning more from finger tapping in parkinson's disease: up and down from dyskinesia to Bradykinesia"], ["Marina Picillo", 2016, "Learning more from finger tapping in parkinson's disease: up and down from dyskinesia to Bradykinesia"], ["Yan Liang", 2016, "Mutation analysis of CHCHD2 in Canadian patients with familial Parkinson's disease"], ["Danielle Moreno", 2016, "Mutation analysis of CHCHD2 in Canadian patients with familial Parkinson's disease"], ["Shilun Fang", 2016, "Mutation analysis of CHCHD2 in Canadian patients with familial Parkinson's disease"], ["Zhengrui Xi", 2016, "Mutation analysis of CHCHD2 in Canadian patients with familial Parkinson's disease"], ["Christos Ganos", 2016, "The long-term outcome of orthostatic tremor"], ["Amit Batla", 2016, "The long-term outcome of orthostatic tremor"], ["Elena Antelmi", 2016, "The long-term outcome of orthostatic tremor"], ["Emmanuelle Apartis", 2016, "The long-term outcome of orthostatic tremor"], ["Carla Cordivari", 2016, "The long-term outcome of orthostatic tremor"], ["Irene Navalpotro-G\u00f3mez", 2016, "The long-term outcome of orthostatic tremor"], ["Lucie Maugest", 2016, "The long-term outcome of orthostatic tremor"], ["Francisco J Palomar", 2016, "The long-term outcome of orthostatic tremor"], ["Marie-Laure Welter", 2016, "The long-term outcome of orthostatic tremor"], ["Bertrand Degos", 2016, "The long-term outcome of orthostatic tremor"], ["Tiago Mestre", 2016, "The long-term outcome of orthostatic tremor"], ["Mar\u00eda T C\u00e1ceres-Redondo", 2016, "The long-term outcome of orthostatic tremor"], ["Filomena Mazzella", 2016, "Cortical plasticity induction by pairing subthalamic nucleus deep-brain stimulation and primary motor cortical transcranial magnetic stimulation in Parkinson's disease"], ["Nina Bahl", 2016, "Cortical plasticity induction by pairing subthalamic nucleus deep-brain stimulation and primary motor cortical transcranial magnetic stimulation in Parkinson's disease"], ["C Gasca-Salas", 2016, "Neurologic diagnostic criteria for functional neurologic disorders"], ["C Colosimo", 2016, "Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP)"], ["J Levin", 2016, "Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP)"], ["T van Eimeren", 2016, "Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP)"], ["R Dodel", 2016, "Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP)"], ["P Nestor", 2016, "Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP)"], ["W Oertel", 2016, "Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP)"], ["G Rabinovici", 2016, "Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP)"], ["J Whitwell", 2016, "Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP)"], ["A Antonini", 2016, "Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP)"], ["F Krismer", 2016, "Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP)"], ["J Kassubek", 2016, "Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP)"], ["B Mollenhauer", 2016, "Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP)"], ["U Muller", 2016, "Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP)"], ["J van Swieten", 2016, "Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP)"], ["LI Golbe", 2016, "Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP)"], ["A Giese", 2016, "Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP)"], ["M Grossman", 2016, "Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP)"], ["JT Yu", 2016, "Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP)"], ["G Wenning", 2016, "Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP)"], ["J Rowe", 2016, "Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP)"], ["Galit Kleiner-Fisman", 2016, "Characterization of movement disorder phenomenology in genetically proven, familial frontotemporal lobar degeneration: a systematic review and meta-analysis"], ["David Fisman", 2016, "Characterization of movement disorder phenomenology in genetically proven, familial frontotemporal lobar degeneration: a systematic review and meta-analysis"], ["Edwin Khoo", 2016, "Characterization of movement disorder phenomenology in genetically proven, familial frontotemporal lobar degeneration: a systematic review and meta-analysis"], ["Binit B Shah", 2016, "Characterization of movement disorder phenomenology in genetically proven, familial frontotemporal lobar degeneration: a systematic review and meta-analysis"], ["James Beck", 2016, "Early Clinical Predictors of Treatment\u2010Resistant and Functional Outcomes in Parkinson's Disease"], ["Roger Kurlan", 2016, "Early Clinical Predictors of Treatment\u2010Resistant and Functional Outcomes in Parkinson's Disease"], ["Robin Elliott", 2016, "Early Clinical Predictors of Treatment\u2010Resistant and Functional Outcomes in Parkinson's Disease"], ["PSG PostCEPT (LABS\u2010PD) Investigators", 2016, "Early Clinical Predictors of Treatment\u2010Resistant and Functional Outcomes in Parkinson's Disease"], ["Julia Hopyan", 2016, "Orthostatic hypotension, cerebral hypoperfusion, and visuospatial deficits in Lewy body disorders"], ["Michelle A Messner", 2016, "Orthostatic hypotension, cerebral hypoperfusion, and visuospatial deficits in Lewy body disorders"], ["James Bower", 2016, "Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers)"], ["Caroline Selai", 2016, "Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers)"], ["Niall P Quinn", 2016, "Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers)"], ["Anette Schrag", 2016, "Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers)"], ["Philip Low", 2016, "Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers)"], ["Marios Pillas", 2016, "Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers)"], ["T van Laar", 2015, "Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson\u2019s disease: the LEAP-study"], ["G Tissingh", 2015, "Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson\u2019s disease: the LEAP-study"], ["G Deuschl", 2015, "Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson\u2019s disease: the LEAP-study"], ["RJ de Haan", 2015, "Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson\u2019s disease: the LEAP-study"], ["RMA de Bie", 2015, "Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson\u2019s disease: the LEAP-study"], ["BR Bloem", 2015, "Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson\u2019s disease: the LEAP-study"], ["B Post", 2015, "Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson\u2019s disease: the LEAP-study"], ["M Dijkgraaf", 2015, "Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson\u2019s disease: the LEAP-study"], ["SR Suwijn", 2015, "Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson\u2019s disease: the LEAP-study"], ["Constant VM Verschuur", 2015, "Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson\u2019s disease: the LEAP-study"], ["Aristotle N Voineskos", 2015, "Genome\u2010wide variant by serum urate interaction in Parkinson's disease"], ["Yun J Kim", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Maria Bozi", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Georgia Xiromerisiou", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Zbigniew Wszolek", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Nobutaka Hattori", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Beom Jeon", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Leonidas Stefanis", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Jessie Theuns", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Gertrud Eckstein", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Aldo Quattrone", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Demetrius M Maraganore", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Ryan J Uitti", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Kuo-Chu Yueh", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Angela Deutschl\u00e4nder", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Owen A Ross", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Stefano Goldwurm", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Yi Zhao", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Andrew A Hicks", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Lisa Wang", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Sung S Park", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Rejko Kr\u00fcger", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Mathias Toft", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["George D Mellick", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Vincent Mok", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Carl Clarke", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Eng K Tan", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Sun J Chung", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Karen E Morrison", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Joanne D Stockton", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Peter Lichtner", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Juei-Jueng Lin", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Barbara Jasinska-Myga", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Peter P Pramstaller", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Jan O Aasly", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Karin Wirdefeldt", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Grazia Annesi", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Christine Van Broeckhoven", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Grzegorz Opala", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Hiroyuki Tomiyama", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Manu Sharma", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Soraya Bardien", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Jonathan Carr", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["David Crosiers", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Gaetan Garraux", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Timothy Lynch", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Georgios M Hadjigeorgiou", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Lasse Pihlstr\u00f8m", 2015, "Large-scale assessment of polyglutamine repeat expansions in Parkinson disease"], ["Joanne Knight", 2015, "Determination of single nucleotide polymorphisms useful to predict response for rasagiline"], ["Anthony Edward Lang", 2015, "Determination of single nucleotide polymorphisms useful to predict response for rasagiline"], ["James Lowery Kennedy", 2015, "Determination of single nucleotide polymorphisms useful to predict response for rasagiline"], ["Ofra Barnett", 2015, "Determination of single nucleotide polymorphisms useful to predict response for rasagiline"], ["Maureen Shannon Collinson", 2015, "Determination of single nucleotide polymorphisms useful to predict response for rasagiline"], ["Lili-Naz Hazrai", 2015, "COLONIC MUCOSAL alpha-SYNUCLEIN LACKS SPECIFICITY AS A BIOMARKER FOR PARKINSON DISEASE Response"], ["John M Woulfe", 2015, "Colonic mucosal \u03b1-synuclein lacks specificity as a biomarker for Parkinson diseaseAuthor Response"], ["Laura Parkkinen", 2015, "Colonic mucosal \u03b1-synuclein lacks specificity as a biomarker for Parkinson diseaseAuthor Response"], ["Madison T Gray", 2015, "Colonic mucosal \u03b1-synuclein lacks specificity as a biomarker for Parkinson diseaseAuthor Response"], ["Claudio Ruffmann", 2015, "Colonic mucosal \u03b1-synuclein lacks specificity as a biomarker for Parkinson diseaseAuthor Response"], ["Lorenzo Pinessi", 2015, "Mutation analysis of CHCHD10 in different neurodegenerative diseases"], ["Bryan J Traynor", 2015, "Mutation analysis of CHCHD10 in different neurodegenerative diseases"], ["Benedetta Nacmias", 2015, "Mutation analysis of CHCHD10 in different neurodegenerative diseases"], ["Elisa Rubino", 2015, "Mutation analysis of CHCHD10 in different neurodegenerative diseases"], ["Julia Keith", 2015, "Mutation analysis of CHCHD10 in different neurodegenerative diseases"], ["Peter St George-Hyslop", 2015, "Mutation analysis of CHCHD10 in different neurodegenerative diseases"], ["Jing Guo", 2015, "Mutation analysis of CHCHD10 in different neurodegenerative diseases"], ["Innocenzo Rainero", 2015, "Mutation analysis of CHCHD10 in different neurodegenerative diseases"], ["Raffaele G Maletta", 2015, "Mutation analysis of CHCHD10 in different neurodegenerative diseases"], ["Amalia C Bruni", 2015, "Mutation analysis of CHCHD10 in different neurodegenerative diseases"], ["Ezequiel I Surace", 2015, "Mutation analysis of CHCHD10 in different neurodegenerative diseases"], ["Sandro Sorbi", 2015, "Mutation analysis of CHCHD10 in different neurodegenerative diseases"], ["Sabrina AM Curcio", 2015, "Mutation analysis of CHCHD10 in different neurodegenerative diseases"], ["Daniela Galimberti", 2015, "Mutation analysis of CHCHD10 in different neurodegenerative diseases"], ["Maria Giovanna Marrosu", 2015, "Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa\u2013carbidopa intestinal gel infusion"], ["Paolo Solla", 2015, "Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa\u2013carbidopa intestinal gel infusion"], ["Antonino Cannas", 2015, "Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa\u2013carbidopa intestinal gel infusion"], ["Cesare Salvatore Mulas", 2015, "Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa\u2013carbidopa intestinal gel infusion"], ["Francesco Marrosu", 2015, "Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa\u2013carbidopa intestinal gel infusion"], ["Paul Larson", 2015, "Gene delivery of neurturin to putamen and substantia nigra in P arkinson disease: A double\u2010blind, randomized, controlled trial"], ["Phillip A Starr", 2015, "Gene delivery of neurturin to putamen and substantia nigra in P arkinson disease: A double\u2010blind, randomized, controlled trial"], ["Barton Guthrie", 2015, "Gene delivery of neurturin to putamen and substantia nigra in P arkinson disease: A double\u2010blind, randomized, controlled trial"], ["Tiffany L Baumann", 2015, "Gene delivery of neurturin to putamen and substantia nigra in P arkinson disease: A double\u2010blind, randomized, controlled trial"], ["Ray Watts", 2015, "Gene delivery of neurturin to putamen and substantia nigra in P arkinson disease: A double\u2010blind, randomized, controlled trial"], ["Christopher Herzog", 2015, "Gene delivery of neurturin to putamen and substantia nigra in P arkinson disease: A double\u2010blind, randomized, controlled trial"], ["Dennis A Turner", 2015, "Gene delivery of neurturin to putamen and substantia nigra in P arkinson disease: A double\u2010blind, randomized, controlled trial"], ["Kathleen Poston", 2015, "Gene delivery of neurturin to putamen and substantia nigra in P arkinson disease: A double\u2010blind, randomized, controlled trial"], ["Mark Stacy", 2015, "Gene delivery of neurturin to putamen and substantia nigra in P arkinson disease: A double\u2010blind, randomized, controlled trial"], ["Raymond T Bartus", 2015, "Gene delivery of neurturin to putamen and substantia nigra in P arkinson disease: A double\u2010blind, randomized, controlled trial"], ["Jaimie M Henderson", 2015, "Gene delivery of neurturin to putamen and substantia nigra in P arkinson disease: A double\u2010blind, randomized, controlled trial"], ["William Marks", 2015, "Gene delivery of neurturin to putamen and substantia nigra in P arkinson disease: A double\u2010blind, randomized, controlled trial"], ["Nicholas Boulis", 2015, "Gene delivery of neurturin to putamen and substantia nigra in P arkinson disease: A double\u2010blind, randomized, controlled trial"], ["Gordon Baltuch", 2015, "Gene delivery of neurturin to putamen and substantia nigra in P arkinson disease: A double\u2010blind, randomized, controlled trial"], ["Stewart Factor", 2015, "Gene delivery of neurturin to putamen and substantia nigra in P arkinson disease: A double\u2010blind, randomized, controlled trial"], ["Richard Simpson", 2015, "Gene delivery of neurturin to putamen and substantia nigra in P arkinson disease: A double\u2010blind, randomized, controlled trial"], ["Ron Alterman", 2015, "Gene delivery of neurturin to putamen and substantia nigra in P arkinson disease: A double\u2010blind, randomized, controlled trial"], ["Sixto Garc\u00eda-Mi\u00f1a\u00far", 2015, "Practical guidelines for managing adults with 22q11. 2 deletion syndrome"], ["Candice Silversides", 2015, "Practical guidelines for managing adults with 22q11. 2 deletion syndrome"], ["Andrea Shugar", 2015, "Practical guidelines for managing adults with 22q11. 2 deletion syndrome"], ["Susan George", 2015, "Practical guidelines for managing adults with 22q11. 2 deletion syndrome"], ["Therese Van Amelsvoort", 2015, "Practical guidelines for managing adults with 22q11. 2 deletion syndrome"], ["Brian Chung", 2015, "Practical guidelines for managing adults with 22q11. 2 deletion syndrome"], ["Donna M McDonald-McGinn", 2015, "Practical guidelines for managing adults with 22q11. 2 deletion syndrome"], ["Gregory Costain", 2015, "Practical guidelines for managing adults with 22q11. 2 deletion syndrome"], ["Cheryl Cytrynbaum", 2015, "Practical guidelines for managing adults with 22q11. 2 deletion syndrome"], ["Wai Lun Alan Fung", 2015, "Practical guidelines for managing adults with 22q11. 2 deletion syndrome"], ["Gabriela Repetto", 2015, "Practical guidelines for managing adults with 22q11. 2 deletion syndrome"], ["Hanna Faghfoury", 2015, "Practical guidelines for managing adults with 22q11. 2 deletion syndrome"], ["Leona Fishman", 2015, "Practical guidelines for managing adults with 22q11. 2 deletion syndrome"], ["Paul Stypulkowski", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Sjaak Deckers", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["William L Allen", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Sameer Sheth", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["James Giordano", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Jens Ellrich", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Joseph Neimat", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Brian Kopell", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Jill Ostrem", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Helen Bronte-Stewart", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Lauren Schrock", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Benjamin D Greenberg", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Kelly E Lyons", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Cameron McIntyre", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Donnie Reymers", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Ludy Shih", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Harrison Walker", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Alexander Kent", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Darin Dougherty", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["David Greene", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Leo Verhagen", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Francisco Ponce", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Coralie De Hemptinne", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Sat Pannu", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Mahlon DeLong", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Hoon-Ki Min", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Scott Stanslaski", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Hokuto Morita", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["David Charles", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Edward Karst", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Robert Gross", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["Hubert Martens", 2015, "Proceedings of the second annual deep brain stimulation think tank: what's in the pipeline"], ["David Tang-Wai", 2015, "Differences in saliency network between Alzheimer\u2019s and parkinson\u2019s disease"], ["Elia Abi\u2010Jaoude", 2015, "Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [11C]\u2010(+)\u2010PHNO and [11C]raclopride \u2026"], ["Paul Sandor", 2015, "Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [11C]\u2010(+)\u2010PHNO and [11C]raclopride \u2026"], ["Barbara Segura", 2015, "Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [11C]\u2010(+)\u2010PHNO and [11C]raclopride \u2026"], ["Ignacio Obeso", 2015, "Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [11C]\u2010(+)\u2010PHNO and [11C]raclopride \u2026"], ["Nancy Lobaugh", 2015, "Imaging changes associated with cognitive abnormalities in Parkinson\u2019s disease"], ["P Mir", 2015, "The long-term outcome of orthostatic tremor: 1450"], ["M C\u00e1ceres-Redondo", 2015, "The long-term outcome of orthostatic tremor: 1450"], ["F Palomar", 2015, "The long-term outcome of orthostatic tremor: 1450"], ["C Ganos", 2015, "The long-term outcome of orthostatic tremor: 1450"], ["E Apartis", 2015, "The long-term outcome of orthostatic tremor: 1450"], ["A Batla", 2015, "The long-term outcome of orthostatic tremor: 1450"], ["E Antelmi", 2015, "The long-term outcome of orthostatic tremor: 1450"], ["I Navalpotro", 2015, "The long-term outcome of orthostatic tremor: 1450"], ["E Roze", 2015, "The long-term outcome of orthostatic tremor: 1450"], ["M Welter", 2015, "The long-term outcome of orthostatic tremor: 1450"], ["S Fox", 2015, "The long-term outcome of orthostatic tremor: 1450"], ["R Erro", 2015, "The long-term outcome of orthostatic tremor: 1450"], ["C Cordivari", 2015, "The long-term outcome of orthostatic tremor: 1450"], ["L Maugest", 2015, "The long-term outcome of orthostatic tremor: 1450"], ["B Degos", 2015, "The long-term outcome of orthostatic tremor: 1450"], ["Ronald F Pfeiffer", 2015, "Gastrointestinal dysfunction in Parkinson's disease"], ["A Valencia", 2015, "Long-term outcomes of subthalamic deep brain stimulation in monogenic Parkinson's disease: 541"], ["S Kalia", 2015, "Long-term outcomes of subthalamic deep brain stimulation in monogenic Parkinson's disease: 541"], ["C Aquino", 2015, "Long-term outcomes of subthalamic deep brain stimulation in monogenic Parkinson's disease: 541"], ["Y Poon", 2015, "Long-term outcomes of subthalamic deep brain stimulation in monogenic Parkinson's disease: 541"], ["E Rogaeva", 2015, "Long-term outcomes of subthalamic deep brain stimulation in monogenic Parkinson's disease: 541"], ["H Ferraz", 2015, "Long-term outcomes of subthalamic deep brain stimulation in monogenic Parkinson's disease: 541"], ["A Lozano", 2015, "Long-term outcomes of subthalamic deep brain stimulation in monogenic Parkinson's disease: 541"], ["M Fallis", 2015, "Long-term outcomes of subthalamic deep brain stimulation in monogenic Parkinson's disease: 541"], ["M Hodaie", 2015, "Long-term outcomes of subthalamic deep brain stimulation in monogenic Parkinson's disease: 541"], ["I Beaulieu-Boire", 2015, "Long-term outcomes of subthalamic deep brain stimulation in monogenic Parkinson's disease: 541"], ["B Shah", 2015, "Characterization of Movement Disorder phenomenology in genetically proven frontotemporal lobar degeneration: A systematic review and meta-analysis: 687"], ["G Kleiner-Fisman", 2015, "Characterization of Movement Disorder phenomenology in genetically proven frontotemporal lobar degeneration: A systematic review and meta-analysis: 687"], ["D Fisman", 2015, "Characterization of Movement Disorder phenomenology in genetically proven frontotemporal lobar degeneration: A systematic review and meta-analysis: 687"], ["E Khoo", 2015, "Characterization of Movement Disorder phenomenology in genetically proven frontotemporal lobar degeneration: A systematic review and meta-analysis: 687"], ["K Aminian", 2015, "Fatigue in Parkinson's disease: The evidence of regional cerebral glucose metabolism abnormalities: 386"], ["B Ballanger", 2015, "The contribution of the insula in Parkinson's disease: A quantitative meta-analysis study: 427"], ["P Boulinguez", 2015, "The contribution of the insula in Parkinson's disease: A quantitative meta-analysis study: 427"], ["M Marion", 2015, "The contribution of the insula in Parkinson's disease: A quantitative meta-analysis study: 427"], ["A Kucyi", 2015, "The impact of amyloid deposition on brain network functional connectivity in Parkinson's disease: 9"], ["M Pondal", 2015, "Transcranial sonography of the substantia nigra in Parkinson's disease (PD) and controls: Distinguishing PD and controls by two different measurement strategies: 1006"], ["A Bassett", 2015, "Investigating prodromal markers of Parkinson's disease in adults with hemizygous 22q11. 2 deletions: 1024"], ["N Butcher", 2015, "Investigating prodromal markers of Parkinson's disease in adults with hemizygous 22q11. 2 deletions: 1024"], ["Pasquale Striano", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Andrea Legati", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Renee L Sears", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["\u00c1ngel Carracedo", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Sheila A Simpson", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Cristina Castro-Fern\u00e1ndez", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Ga\u00ebl Nicolas", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Didier Hannequin", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Vivek K Unni", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Uriel L\u00f3pez-S\u00e1nchez", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Henry Paulson", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Joanna C Jen", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Daniel H Geschwind", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Marja W Wessels", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Cyril Goizet", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Marc Sitbon", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["St\u00e9phanie Cubizolle", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Anne-Claire Richard", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Martin Paucar", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Fran\u00e7ois Tison", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Per Svenningsson", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Suppachok Kirdlarp", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Mar\u00eda-Jes\u00fas Sobrido", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["J\u00e9r\u00e9mie Pariente", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Zosia Miedzybrodzka", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Jean-Luc Battini", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Suppachok Wetchaphanphesat", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Dominique Campion", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Francois Boller", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Naomi S Salins", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Donatella Giovannini", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Elizabeth Spiteri", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Michele Yang", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Giovanni Coppola", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Eliana Marisa Ramos", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Witoon Mitarnun", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Jo\u00e3o RM Oliveira", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Beatriz Quint\u00e1ns", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Brent L Fogel", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Olivier Vanakker", 2015, "Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export"], ["Zeshan Ahmed", 2015, "Minimal change multiple system atrophy: an aggressive variant?"], ["Lili\u2010Naz Hazrati", 2015, "Minimal change multiple system atrophy: an aggressive variant?"], ["Masatoyo Nishizawa", 2015, "Minimal change multiple system atrophy: an aggressive variant?"], ["LK Prashanth", 2015, "Minimal change multiple system atrophy: an aggressive variant?"], ["Andrew J Lees", 2015, "Minimal change multiple system atrophy: an aggressive variant?"], ["Igor N Petrovic", 2015, "Minimal change multiple system atrophy: an aggressive variant?"], ["Yasmine T Asi", 2015, "Minimal change multiple system atrophy: an aggressive variant?"], ["Tamas Revesz", 2015, "Minimal change multiple system atrophy: an aggressive variant?"], ["Tetsutaro Ozawa", 2015, "Minimal change multiple system atrophy: an aggressive variant?"], ["Janice L Holton", 2015, "Minimal change multiple system atrophy: an aggressive variant?"], ["Helen Ling", 2015, "Minimal change multiple system atrophy: an aggressive variant?"], ["Y Chu", 2015, "Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with \u03b1-synucleinopathies"], ["RT Bartus", 2015, "Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with \u03b1-synucleinopathies"], ["TL Baumann", 2015, "Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with \u03b1-synucleinopathies"], ["L Brown", 2015, "Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with \u03b1-synucleinopathies"], ["BR Kruegel", 2015, "Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with \u03b1-synucleinopathies"], ["EM Johnson Jr", 2015, "Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with \u03b1-synucleinopathies"], ["CD Herzog", 2015, "Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with \u03b1-synucleinopathies"], ["Laura Fitzpatrick", 2015, "Response to clozapine in a clinically identifiable subtype of schizophrenia"], ["Alina Guna", 2015, "Response to clozapine in a clinically identifiable subtype of schizophrenia"], ["Jessica McNeil", 2015, "Sit Less, Stand More: A Randomized Point-of-decision Prompt Intervention To Reduce Sedentary Time: 2628 Board# 1 May 29, 1: 00 PM-3: 00 PM"], ["Anne Bassett", 2015, "Personalizing treatment of schizophrenia: Clozapine response in a molecular subtype"], ["Eva Chow", 2015, "Personalizing treatment of schizophrenia: Clozapine response in a molecular subtype"], ["Nancy Butcher", 2015, "Personalizing treatment of schizophrenia: Clozapine response in a molecular subtype"], ["Chong-Tin Tan", 2015, "Helicobacter Pylori Infection is Associated with Worse Severity of Parkinson\u2019s Disease (P3. 018)"], ["Jamunarani Vadivelu", 2015, "Helicobacter Pylori Infection is Associated with Worse Severity of Parkinson\u2019s Disease (P3. 018)"], ["Sheau Phing Ang", 2015, "Helicobacter Pylori Infection is Associated with Worse Severity of Parkinson\u2019s Disease (P3. 018)"], ["Abdul Malik Thalha", 2015, "Helicobacter Pylori Infection is Associated with Worse Severity of Parkinson\u2019s Disease (P3. 018)"], ["Sheang Wen Ng", 2015, "Helicobacter Pylori Infection is Associated with Worse Severity of Parkinson\u2019s Disease (P3. 018)"], ["Chiun Khang Kiew", 2015, "Helicobacter Pylori Infection is Associated with Worse Severity of Parkinson\u2019s Disease (P3. 018)"], ["Chia Ming Yeat", 2015, "Helicobacter Pylori Infection is Associated with Worse Severity of Parkinson\u2019s Disease (P3. 018)"], ["Shen Yang Lim", 2015, "Helicobacter Pylori Infection is Associated with Worse Severity of Parkinson\u2019s Disease (P3. 018)"], ["Norlinah Ibrahim", 2015, "Helicobacter Pylori Infection is Associated with Worse Severity of Parkinson\u2019s Disease (P3. 018)"], ["Siew Kian Chow", 2015, "Helicobacter Pylori Infection is Associated with Worse Severity of Parkinson\u2019s Disease (P3. 018)"], ["Bernd Krone", 2015, "Vaccination, infection, and the risk for multiple sclerosis"], ["John M Grange", 2015, "Vaccination, infection, and the risk for multiple sclerosis"], ["BB Shah", 2015, "Repetitive transcranial magnetic stimulation plus standardized suggestion of benefit for functional movement disorders: an open label case series"], ["LV Kalia", 2015, "Repetitive transcranial magnetic stimulation plus standardized suggestion of benefit for functional movement disorders: an open label case series"], ["C Gunraj", 2015, "Repetitive transcranial magnetic stimulation plus standardized suggestion of benefit for functional movement disorders: an open label case series"], ["Eduard Z Yakupov", 2015, "Levodopa\u2010carbidopa intestinal gel in advanced Parkinson's disease: final 12\u2010month, open\u2010label results"], ["Oksana Suchowersky", 2015, "Levodopa\u2010carbidopa intestinal gel in advanced Parkinson's disease: final 12\u2010month, open\u2010label results"], ["Coleen M Hall", 2015, "Levodopa\u2010carbidopa intestinal gel in advanced Parkinson's disease: final 12\u2010month, open\u2010label results"], ["Malcolm Steiger", 2015, "Levodopa\u2010carbidopa intestinal gel in advanced Parkinson's disease: final 12\u2010month, open\u2010label results"], ["A Jon Stoessl", 2015, "The Saskatchewan Movement Disorders Program: Commitment Pays Off"], ["Th\u00e9r\u00e8se AMJ van Amelsvoort", 2015, "Movement disorders and other motor abnormalities in adults with 22q11. 2 deletion syndrome"], ["Chong Tin Tan", 2015, "Rapid\u2010Onset Dystonia\u2010Parkinsonism in a Chinese Girl with a De Novo ATP1A3 c. 2267G> A (p. R756H) Genetic Mutation"], ["Laurie J Ozelius", 2015, "Rapid\u2010Onset Dystonia\u2010Parkinsonism in a Chinese Girl with a De Novo ATP1A3 c. 2267G> A (p. R756H) Genetic Mutation"], ["Azlina Ahmad\u2010Annuar", 2015, "Rapid\u2010Onset Dystonia\u2010Parkinsonism in a Chinese Girl with a De Novo ATP1A3 c. 2267G> A (p. R756H) Genetic Mutation"], ["Allison Brashear", 2015, "Rapid\u2010Onset Dystonia\u2010Parkinsonism in a Chinese Girl with a De Novo ATP1A3 c. 2267G> A (p. R756H) Genetic Mutation"], ["Jamunarani S Vadivelu", 2015, "Helicobacter pylori infection is associated with worse severity of Parkinson's disease"], ["David E Fleck", 2015, "Placebo effect of medication cost in Parkinson disease: a randomized double-blind study"], ["Matthew S Smith", 2015, "Placebo effect of medication cost in Parkinson disease: a randomized double-blind study"], ["Michael J Linke", 2015, "Placebo effect of medication cost in Parkinson disease: a randomized double-blind study"], ["Alok Dwivedi", 2015, "Placebo effect of medication cost in Parkinson disease: a randomized double-blind study"], ["Christi Banks", 2015, "Placebo effect of medication cost in Parkinson disease: a randomized double-blind study"], ["Andrew Gao", 2015, "Colonic mucosal \u03b1-synuclein lacks specificity as a biomarker for Parkinson disease"], ["Lili-Naz Hazrati", 2015, "Colonic mucosal \u03b1-synuclein lacks specificity as a biomarker for Parkinson disease"], ["Amaal Al Dakheel", 2015, "Colonic mucosal \u03b1-synuclein lacks specificity as a biomarker for Parkinson disease"], ["M Samuel", 2015, "Impulse Control Disorders in Parkinson\u2019s Disease: Management, controversies, and potential approaches"], ["RG Brown", 2015, "Impulse Control Disorders in Parkinson\u2019s Disease: Management, controversies, and potential approaches"], ["MS Okun", 2015, "Impulse Control Disorders in Parkinson\u2019s Disease: Management, controversies, and potential approaches"], ["JM Brotchie", 2015, "Impulse Control Disorders in Parkinson\u2019s Disease: Management, controversies, and potential approaches"], ["K Ray Chaudhuri", 2015, "Impulse Control Disorders in Parkinson\u2019s Disease: Management, controversies, and potential approaches"], ["WR Galpern", 2015, "Impulse Control Disorders in Parkinson\u2019s Disease: Management, controversies, and potential approaches"], ["M Rodriguez-Oroz", 2015, "Impulse Control Disorders in Parkinson\u2019s Disease: Management, controversies, and potential approaches"], ["Pieter Roos", 2015, "Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study"], ["Hyman M Schipper", 2015, "Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study"], ["Vince Dodelet", 2015, "Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study"], ["Jennifer Harman", 2015, "Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study"], ["Maria Rodriguez\u2010Oroz", 2015, "Management of impulse control disorders in Parkinson's disease: controversies and future approaches"], ["Michael Samuel", 2015, "Management of impulse control disorders in Parkinson's disease: controversies and future approaches"], ["Melissa J Nirenberg", 2015, "Management of impulse control disorders in Parkinson's disease: controversies and future approaches"], ["Wendy R Galpern", 2015, "Management of impulse control disorders in Parkinson's disease: controversies and future approaches"], ["Kallol Ray Chaudhuri", 2015, "Management of impulse control disorders in Parkinson's disease: controversies and future approaches"], ["Richard G Brown", 2015, "Management of impulse control disorders in Parkinson's disease: controversies and future approaches"], ["Isabelle Boileau", 2015, "Salience network and parahippocampal dopamine dysfunction in memory\u2010impaired Parkinson disease"], ["Sarah Duff\u2010Canning", 2015, "Salience network and parahippocampal dopamine dysfunction in memory\u2010impaired Parkinson disease"], ["Zafiris J Daskalakis", 2015, "Investing in the future: stimulation of the medial prefrontal cortex reduces discounting of delayed rewards"], ["Ji-Hyun Ko", 2015, "Imaging striatal microglial activation in patients with Parkinson\u2019s disease"], ["Mark F Jacobs", 2015, "Imaging striatal microglial activation in patients with Parkinson\u2019s disease"], ["Alan A Wilson", 2015, "Imaging striatal microglial activation in patients with Parkinson\u2019s disease"], ["Rostom Mabrouk", 2015, "Imaging striatal microglial activation in patients with Parkinson\u2019s disease"], ["RG Harper", 2015, "Eggshell porosity covaries with egg size among female House Wrens (Troglodytes aedon), but is unrelated to incubation onset and egg-laying order within clutches"], ["WB Jaeckle", 2015, "Eggshell porosity covaries with egg size among female House Wrens (Troglodytes aedon), but is unrelated to incubation onset and egg-laying order within clutches"], ["L Podgorski", 2015, "Eggshell porosity covaries with egg size among female House Wrens (Troglodytes aedon), but is unrelated to incubation onset and egg-laying order within clutches"], ["EK Bowers", 2015, "Eggshell porosity covaries with egg size among female House Wrens (Troglodytes aedon), but is unrelated to incubation onset and egg-laying order within clutches"], ["SK Sakaluk", 2015, "Eggshell porosity covaries with egg size among female House Wrens (Troglodytes aedon), but is unrelated to incubation onset and egg-laying order within clutches"], ["CF Thompson", 2015, "Eggshell porosity covaries with egg size among female House Wrens (Troglodytes aedon), but is unrelated to incubation onset and egg-laying order within clutches"], ["A White", 2015, "Eggshell porosity covaries with egg size among female House Wrens (Troglodytes aedon), but is unrelated to incubation onset and egg-laying order within clutches"], ["Isabelle Beaulieu\u2010Boire", 2015, "Behavioral effects of levodopa"], ["Charles Duyckaerts", 2015, "Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease"], ["Shinsuke Fujioka", 2015, "Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease"], ["Zbigniew K Wszolek", 2015, "Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease"], ["Adolfo L\u00f3pez De Munain", 2015, "Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease"], ["Andreas Puschmann", 2015, "Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease"], ["Margherita Canesi", 2015, "Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease"], ["Gianni Pezzoli", 2015, "Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease"], ["Maria T Giordana", 2015, "Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease"], ["Javier Ruiz-Mart\u00ednez", 2015, "Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease"], ["Lorraine N Clark", 2015, "Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease"], ["Carles Gaig", 2015, "Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease"], ["Jose F Marti-Masso", 2015, "Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease"], ["Howard I Hurtig", 2015, "Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease"], ["Vivianna M Van Deerlin", 2015, "Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease"], ["Andre Maues De Paula", 2015, "Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease"], ["Kazuko Hasegawa", 2015, "Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease"], ["Isidre Ferrer", 2015, "Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease"], ["John Q Trojanowski", 2015, "Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease"], ["Karen S Marder", 2015, "Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease"], ["Valentina Bessi", 2015, "Mutation analysis of patients with neurodegenerative disorders using NeuroX array"], ["Andrea Tedde", 2015, "Mutation analysis of patients with neurodegenerative disorders using NeuroX array"], ["Mike A Nalls", 2015, "Mutation analysis of patients with neurodegenerative disorders using NeuroX array"], ["Rachel Hung", 2015, "Mutation analysis of patients with neurodegenerative disorders using NeuroX array"], ["RA Armstrong", 2015, "Corticobasal degeneration and dementia"]]}